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In December, 2017 the National Advisory Committee on 
Drugs and Alcohol (NACDA) published the findings of the 
third study estimating the prevalence of problematic 
opiate use in Ireland.1 An opiate is a drug containing 
opium or any of its derivatives that acts as a sedative and 
narcotic. Examples include heroin, methadone, morphine, 
codeine, hydrocodone, fentanyl and tramadol. Heroin 
is synthesised from morphine, a naturally occurring 
substance extracted from the seed pod of the Asian 
opium poppy plant,2 and is available in three forms: a 
white power, a brown powder or a black sticky substance 
known as ‘black tar heroin’. 
Capture-recapture studies 
National 3-source capture-recapture (CRC) studies to provide statistically 
valid estimates of the prevalence of opiate drug use in the Irish population 
were commissioned by the National Advisory Committee on Drugs and 
Alcohol (NACDA) and undertaken in 20013 and 2006.4 The three data sources 
used were the Central Treatment List (of clients on methadone), the Hospital 
In-Patient Enquiry scheme and the Garda PULSE data. 
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In brief
Supporting community-based organisations’ 
use of evidence is an effective way to link 
research to action in health programmes. One 
approach to this work is to develop a strategy 
of community-based knowledge transfer and 
exchange to facilitate the use of research 
evidence in service planning and delivery. 
Researchers working on this topic have identified a 
number of activities that are key to the success of 
these strategies: fostering a culture favourable to the 
use of research evidence and which recognises its 
importance in decision-making; providing evidence that 
is directly relevant to the work of community-based 
organisations; supporting activities that link research 
evidence to action; and, evaluating these efforts. 
Community-based organisations have a key role 
in implementing the actions in Reducing harm, 
supporting recovery. In fulfilling this role, they will 
need support in finding, selecting and using evidence 
in decision-making and implementing the findings of 
research in service delivery and advocacy work. One 
obstacle to increasing the effective use of evidence 
in non-governmental, voluntary and community-
based services has been the lack of material tailored 
to the needs of these stakeholders and providing 
clearly written, accessible and persuasive guidance 
on identifying and implementing research findings. 
There has been substantial improvement in this area in 
recent years. In the United Kingdom, the third sector 
supports a number of organisations who specialise in 
guiding organisations through the steps of evidence-
based decision making, and the volume of literature 
supporting this work has grown substantially over the 
past few years.
In this issue, we highlight a new resource published by 
the EMCDDA which provides services with an excellent 
introduction for anyone attempting to understand 
the role that research evidence can play in making 
their work more effective, sustainable and impactful. 
The resource, Health and social responses to drug 
problems: a European guide aims to encourage a way of 
thinking around how to respond to particular problems 
in particular settings. It provides a brief overview of 
current knowledge on a number of significant drug-
related issues and attempts to answer what we know 
already about the issue, what works, and what can be 
done to respond to it. The guide is supported by an 
online platform on the EMCDDA’s best practice portal. 
It is a companion document to the EMCDDA’s report 
on the drugs market. The two documents complement 
each other and represent significant progress in 
the work of building an informed, empowered and 
confident community response to problem drug use.
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A third study using the CRC method was commissioned 
by the NACDA in 2014.1 In this research, four data sources 
were utilised: (1) drug treatment clinic data; (2) information 
from general practice; (3) prison records; and (4) statistics 
provided by the Irish Probation Service. This article highlights 
some of the study findings.
Prevalence of opiate use
Tables 1 and 2 show prevalence estimates of opiate use in 
the Republic of Ireland. For the current study, data from the 
four sources indicated that the national prevalence estimate 
of opiate users in 2014 was between 18,720 and 21,454. The 
point estimate was 18,988, giving a rate of 6.18 per thousand 
population aged 15—64 years (95% CI: 6.09—6.98). 
Seventy-one per cent of the estimated number of opiate 
users lived in Dublin. The estimates for Dublin were 13,458 
(95% CI: 12,564—14,220), suggesting a population rate of 15.15 
per thousand population. The corresponding figures for 2006 
were 14,909 (95% CI: 13,737—16,450) with a population rate 
of 17.6 per thousand population. The prevalence for the rest 
of Ireland (excluding Dublin) was determined to be 5530 (95% 
CI: 5406—8023). This also represents a slight decrease when 
compared to estimates from 2006 (5586, 95% CI: 4399—7126). 
Sixty-nine per cent of opiate users in 2014 were male. 
In terms of regional differences, County Sligo had the lowest 
prevalence of opiate use with a rate of 0.37 per thousand 
population (95% CI: 0.21—1.73). Other counties with 
prevalence rates lower than 1.0 per thousand were Donegal, 
Leitrim, Mayo and Monaghan. 
With regard to city differences, after Dublin City, Limerick 
City had the highest rate of use at 8.82 per thousand 
population (95% CI: 7.11—13.16) followed by Waterford City 
(6.72, 95% CI: 5.24—15.12) and Cork City (5.67, 95% CI: 
4.91—6.71). Galway City had the lowest prevalence of opiate 
use at 1.93 per thousand (95% CI: 1.55—2.73).
Trends 
The following trends were observed in the study results:
• There has been a slight decrease in opiate use both 
inside and outside of Dublin when compared to 2006. 
• The rate of opiate use among males and females aged 
15—24 years has continued to decline.
• More than one-half (60%) of the State’s opiate users are 
in the 35—64 age group, compared to less than one-third 
in 2006, suggesting a definite ageing cohort effect. 
Conclusions
Findings from the current 4-source CRC study suggest that 
opiate use in Ireland has stabilised. Nevertheless, the study 
authors highlight that there is limited validity in making direct 
comparisons between studies and that none of the slight 
decreases observed were statistically significant.
Seán Millar
1 Hay G, Jaddoa A, Oyston J, Webster J, Van Hout MC,  
Rael dos Santos A (2017) Estimating the prevalence of 
problematic opiate use in Ireland using indirect statistical 
methods. Dublin: National Advisory Committee on Drugs and 
Alcohol. http://www.drugsandalcohol.ie/27233/ 
2 National Institute on Drug Abuse (2017) DrugFacts: Heroin. 
https://www.drugabuse.gov/publications/drugfacts/heroin
3 Kelly A, Carvalho M and Teljeur C (2003) Prevalence of opiate 
use in Ireland 2000–2001: a 3 -source capture recapture study. 
Dublin: Stationery Office. http://www.drugsandalcohol.ie/5942/
4 Kelly A, Teljeur C and Carvalho M (2009) Prevalence of opiate use 
in Ireland 2006: a 3- source capture recapture study. Dublin: 
Stationery Office. http://www.drugsandalcohol.ie/12695/
Table 2: Estimated prevalence of opiate use in Ireland for 2001, 2006 and 2014
2001 2006 2014
Area Estimate Lower 
bound
Upper 
bound
Rate/1000 
population
Estimate Lower 
bound
Upper 
bound
Rate/1000 
population
Estimate Lower 
bound
Upper 
bound
Rate/1000 
population
Dublin 12,456 11,519 13,711 15.9 14,909 13,737 16,450 17.6 13,458 12,564 14,220 15.15
Rest of 
Ireland
2225 1934 2625 1.2 5886 4399 7126 2.9 5530 5406 8023 2.53
State total 14,681 13,404 15,819 5.6 20,790 18,136 23,576 7.2 18,988 18,720 21,454 6.18
Source: NACDA, 2017
Dr Gordon Hay of the Public 
Health Institute, Liverpool 
John Moores University, 
and author of the problem 
opiate use study
New estimates of  
problem opiate use continued
Table 1: Summary of prevalence estimates  
of opiate use in Ireland, 2014
Area Estimate Lower 
bound
Upper 
bound
Rate/1000 
population
Dublin 13,458 12,564 14,220 15.15
Rest of Ireland 5530 5406 8023 2.53
Age group
15—24 years 1092 1076 1234 1.88
25—34 years 6672 6578 7539 8.84
35—64 years 11,224 11,065 12,681 6.46
Gender
Female 5966 5882 6741 3.86
Male 13,022 12,838 14,713 8.52
Source: NACDA, 2017
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implicated increased by 110% since 2010: 
• Cocaine-related deaths have been increasing since 2010, 
with 44 deaths reported in 2015 compared to 21 in 2010.
 
Alcohol was implicated in 107 deaths (31% of all poisonings):
• Alcohol alone was responsible for 14% (n=47) of all 
poisoning deaths in 2015.
Non-poisoning deaths in 2015
The number of non-poisoning deaths deceased by 2%, from 
355 in 2014 to 347 in 2015. The main causes of non-poisoning 
deaths were hanging (83, 24%) and cardiac events (55, 16%):
• Of those who died as a result of hanging, over one-half 
(59%) had a history of mental health problems.
Trends from 2004 to 2015
In the 12-year period 2004–2015, a total of 7,422 poisoning 
deaths and deaths among drug users met the criteria for 
inclusion in the NDRDI database. The number of deaths 
increased by 61% during this period, from 431 in 2004 to 695 
in 2015.
Deaths among injectors
People who were injecting at the time of the incident that 
led to their death represented 8% of all drug-related deaths 
in 2015 (Table 2). Of these deaths:
• 93% were male.
• 89% were poisoning deaths.
• 52% died in Dublin city.
• 94% of the poisoning deaths involved opiates.
Of those injectors who died in 2015 of a poisoning death 
which involved opiates: 
• 40% were not alone at the time of the incident that led 
to their death.
• 20% injected in a public place.
• 27% involved a single opiate type drug.
Ena Lynn and Suzi Lyons
1 Health Research Board (2017) National Drug-Related Deaths 
Index 2004 to 2015 data. Dublin: Health Research Board.  
http://www.drugsandalcohol.ie/28086/
PREVALENCE AND CURRENT SITUATION 
Drug-related  
deaths and deaths 
among drug users 
2004–2015 
The HRB published the latest figures from the National Drug-
Related Deaths Index (NDRDI) in December 2017.1 The new 
bulletin presents an overview of trends due to poisoning 
(overdose) by alcohol and/or other drugs, and deaths among 
drug users (non-poisoning) in the period 2004–2015 (Figure 1). 
In the 12-year period 2004–2015, there were a total of 7,422 
drug-related deaths (Table 1): 
• 4,222 (57%) were due to poisoning.
• 3,200 (43%) were due to non-poisoning. 
In 2015, there were 695 deaths (poisoning and non-poisoning 
combined), marginally lower than the number reported in 
2014 (n=719):  
• Median age for all deaths in 2015 was 41 years and 72% 
(n=503) of all deaths were male.
• There were approximately 20,000 of potential life years 
lost because of drug-related deaths in 2015.
Drug-related deaths in 2015 among injectors: 
•  8% of all deaths were among injectors.
• 52% of injectors died in Dublin city.
Poisoning deaths in 2015
The annual number of poisoning deaths decreased by 
4%, from 364 in 2014 to 348 in 2015. Almost two-thirds of 
poisoning deaths involved polydrugs, with an average of four 
different drugs involved. Benzodiazepines were the most 
common drug group implicated in polydrug deaths. 
Prescription drugs were implicated in two out of three 
poisoning deaths:
• Diazepam (a benzodiazepine) was the most common 
single prescription drug implicated in almost one-third 
(101, 29%) of all poisonings.
• Methadone was implicated in one-quarter of poisonings  
(86, 25%). 
• Pregabalin-related deaths (an antiepileptic drug also 
prescribed for chronic pain and some anxiety conditions) 
increased by 69%, from 26 deaths in 2014 to 44 in 2015.
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Drug-related deaths 2004–2015 continued
Figure 1: National Drug-Related Deaths Index, 2015 data
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Table 1: Number of deaths, by year, NDRDI 2004 to 2015 (n=7422) 
 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
All deaths (total) 431 503 554 620 628 656 607 645 660 704 719 695
Poisonings (4222) 266 301 326 387 386 372 339 377 356 400 364 348
Poisonings male 175 199 228 270 274 254 251 274 264 273 263 230
Poisonings female 91 102 98 117 112 118 88 103 92 127 101 118
Median age 40 39 36 36 38 38 40 39 40 41 39 41
Non-poisonings (3200) 165 202 228 233 242 284 268 268 304 304 355 347
Non-poisonings male 153 176 192 177 196 212 207 218 233 236 278 273
Non-poisonings female 12 26 36 56 46 72 61 50 71 68 77 74
Median age trauma 27 27 27 28 28 30 32 30 31 34 33 34
Median age medical 38 38 43 42 42 40 44 45 46 47 47 49
Table 2: Individual deaths among injectors, NDRDI 2004 to 2015 (n=628)
 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
All NDRDI deaths 431 503 554 620 628 656 607 645 660 704 719 695
Injectors at time of death  
(% of all deaths)
34 
(7.9)
49 
(9.7)
61 
(11.0)
55 
(8.9)
67 
(10.7)
69 
(10.5)
50 
(8.2)
47 
(7.3)
37 
(5.6)
49 
(7.0)
56 
(7.8)
54 
(7.8)
All injector deaths 34 49 61 55 67 69 50 47 37 49 56 54
Male 31 43 55 40 47 58 45 41 32 42 49 50
Female ~ 6 6 15 20 11 5 6 5 7 7 ~
Place of incident*
Dublin City * * * * * * * * 21 28 29 28
Outside of Dublin City * * * * * * * * 16 21 27 26
Type of death
Poisoning 31 42 56 52 54 56 44 42 35 47 52 48
Non-poisoning ~ 7 5 ~ 13 13 6 5 ~ ~ ~ 6
All poisoning deaths 266 301 326 387 386 372 339 377 356 400 364 348
Poisoning deaths involving injectors (% of 
all poisoning deaths)
31 
(11.7)
42 
(14.9)
56 
(17.2)
52 
(13.4)
54 
(14.0)
56 
(15.1)
44 
(13.0)
42 
(11.1)
35 
(9.8)
47 
(11.8)
52 
(14.3)
48 
(13.8)
Poisoning deaths among injectors 
involving opiates of whom:
30 39 50 48 51 54 41 39 32 46 50 45
Deceased was not alone 9 23 24 24 29 32 20 17 17 17 23 18
Deceased was in a public place 8 10 17 13 7 12 7 5 5 7 18 9
Death was caused by a single opiate drug 19 12 24 15 13 22 20 12 6 15 14 12
~ Less than five deaths. 
* NDRDI.
Drug-related deaths 2004-2015 continued
This was the question posed for a rapid evidence review by 
NHS Scotland2 to inform a conference held by the Scottish 
Government along with the Partnership for Action on Drugs 
in Scotland (PADS) in July 2017 entitled ‘Drug Policy through a 
Health Lens’.
Methodology
The report provided a combination of findings from the 
evidence based on the critical appraisal of systematic reviews 
and grey literature reports.
Findings
The evidence was divided into three categories listed as follows: 
• Seek — engagement and access to services 
• Keep — characteristics of treatment and support 
• Treat — benefits of treatment
Drugs-related deaths 
rapid evidence 
review: keeping 
people safe
In the context of rising drug-related deaths, and an 
increasingly vulnerable ageing cohort of people with 
drug problems,1 what does the evidence tell us about 
keeping people safe?
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treatment outcomes for older drug users. A distinction has 
been made between early onset and late onset of drug 
problem use with important implications for treatment and 
recovery approaches. Age-appropriate support for this 
group is important, including involvement of multidisciplinary 
health professionals (due to complex mental and physical 
ill-health), the importance of understanding polydrug use 
to reduce drug-related harms, and ensuring that treatment 
plans are pragmatic and tailored to their multiple issues. 
There is limited evidence available for identifying gender, 
ethnicity or social class differences in effectiveness  
of outcomes.  
3. Treat — benefits of treatment 
The mortality risk of people with opioid dependence is 
reduced when in substitution treatment.7 Finding the balance 
between optimal dosage and remaining in treatment tends 
to have the most positive impact on outcomes. Medication-
focused approaches were found to have better retention rates 
(compared to placebo or no medication), but medications 
should be modified according to the individual’s requirements 
with consideration for the needs of vulnerable older users. 
Evidence suggests that where previous treatments have been 
unsuccessful, older entrenched heroin users may find that 
heroin-assisted approaches may be more appropriate. 
Anne Doyle 
1 For the purpose of the review, older people with a drug problem are 
categorised as those aged over 35 years who experience health and 
social harms related to their own drug use. 
2 Dickie E, Arnot J and Reid G (2017) Drugs-related deaths rapid 
evidence review: keeping people safe. Edinburgh: NHS Health 
Scotland. Available online at http://www.healthscotland.scot/
media/1609/drugs-related-deaths-rapid-evidence-review.pdf 
3 Harm reduction services include needle and syringe programmes, 
supervised drug consumption clinics, and methadone maintenance.
4 Fernandes RM, Cary M, Duarte G, et al. (2017) Effectiveness of needle 
and syringe programmes in people who inject drugs – an overview of 
systematic reviews. BMC Public Health, 17(1): 309.
5 Giglio RE, Li G and DiMaggio CJ (2015) Effectiveness of bystander 
naloxone administration and overdose education programs: a meta-
analysis. Inj Epidemiol, 2(1): 10.
6 McDonald R and Strang J (2016) Are take‐home naloxone 
programmes effective? Systematic review utilizing application of the 
Bradford Hill criteria. Addiction, 111(7): 1177–87.
7 Sordo L, Barrio G, Bravo MJ, et al. (2017) Mortality risk during and 
after opioid substitution treatment: systematic review and meta-
analysis of cohort studies. BMJ, 357: J1550.
8 Timko C, Schultz NR, Cucciare MA, et al. (2016) Retention in 
medication-assisted treatment for opiate dependence: a systematic 
review. J Addict Dis, 35(1): 22–35.
9 Psychosocial interventions include contingency management, 
cognitive behavioural therapy (CBT), motivational interviewing, 
counselling, mutual aid, and telephone/web-based support.
10 Dugosh K, Abraham A, Seymour B, et al. (2016) A systematic review 
on the use of psychosocial interventions in conjunction with 
medications for the treatment of opioid addiction. J Addict Med, 
10(2): 91–101.
11 Contingency management involves giving patients tangible rewards 
to reinforce positive behaviours such as abstinence. 
12 Age-specific issues were reported as having comorbidities (physical 
and mental health); polydrug use; increased social exclusion; feelings 
of moral failing; fear of judgement within services; and stigmas 
due to mental health issues, thus preventing older drug users from 
accessing services.
1. Seek — engagement and access to services
Many complex barriers exist preventing older people seeking 
and maintaining support for a drug problem, including 
financial restrictions, negative perceptions of services, 
feelings of shame and stigma, loneliness and isolation, and 
having multiple health issues due to their long-term drug 
use. The vulnerable nature of this group means that they 
are not accessing services and, when they do, they are 
frequently dropping out. In order to support individuals to 
access services and treatments, these psychological and 
social barriers need to be addressed. In response to this,  
the evidence from the review found that using a more holistic 
approach tailored to the individual improves effectiveness of 
interventions, increases motivation, and prevents dropout.
The review found that blood-borne viruses and risk behaviours 
are reduced when individuals engage with treatment and harm 
reduction services.3,4 In addition, the likelihood of recovery 
from overdose is increased by the use and awareness of take-
home naloxone programmes. Providing training and education 
to users and their families and peers on recognising signs of 
overdose and how to intervene enables them to intervene 
and potentially save a life.5,6 Before and upon release from 
prison is a critical time for providing support to drug users, 
and the evidence demonstrates that drug-related deaths 
can be prevented if prison staff are sufficiently trained in 
harm reduction practices and risks of overdose. Pre-release 
education on overdose risks and prevention, liaising with 
addiction services upon release, and training for prisoners 
with a history of drug abuse and their families on overdose 
awareness and naloxone use were indicators of good practice.
2.  Keep — characteristics of treatment  
and support
The first four weeks of treatment and the first four weeks 
upon leaving treatment have been identified as periods of 
high-risk for drug-related deaths and, as such, are critical 
intervention points to prevent such deaths.7 Having clear 
re-engagement processes and procedures for those moving 
through treatment and for those who have disengaged are an 
important factor in engagement.  
The review data indicate that medications should not be 
viewed as a ‘one size fits all’ and each individual should be 
considered as an individual. Regularly involving users and 
their families in drug prescribing and treatment options is 
important. Updating and reviewing care plans and adjusting 
drug dosage depending on effectiveness have been 
highlighted as good practice indicators along with strategies 
and processes to engage and maintain continuity of care.8 
For those with opioid dependence, the most positive 
outcomes for remaining in treatment and for benefits 
from treatment (e.g. reduced drug use) were seen when a 
person-centred, holistic approach, including psychosocial 
interventions,9 is delivered in conjunction with medication-
assisted treatment.10 There is limited but growing evidence 
that contingency management11 is effective in increasing 
treatment retention and promoting abstinence from drugs. 
Awareness of and subsequent staff training for age-specific 
issues12 was identified as having a positive impact on 
Drugs-related deaths rapid review  
continued
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knowledge, attitudes 
and stigma
Recent research published by HIV Ireland examined national 
HIV knowledge and attitudes and the stigma associated 
with HIV.1 HIV Ireland is a registered charity operating at 
local, national and European levels. The principal aim of the 
organisation is to contribute towards a significant reduction 
in the incidence and prevalence of HIV in Ireland and towards 
the realisation of an AIDS-free generation. The present study 
involved the development of two surveys. The first survey 
aimed to measure knowledge and attitudes among the 
general Irish population. The second survey measured stigma 
and the experiences of those living with HIV. Subjects were 
required to be 18 years of age or older and the surveys were 
completed by 1,013 and 168 respondents, respectively. 
HIV knowledge and attitudes among the 
general public
Almost all adults (98%) correctly thought that HIV can 
be transmitted by sharing needles and syringes. A similar 
proportion correctly thought that HIV can be transmitted  
by a man and a woman, or a man and a man, having sex 
without a condom. However, the study found that myths  
in relation to HIV transmission remain and that young people 
had less correct knowledge than older people in relation  
to most methods of HIV transmission. Misperceptions 
regarding HIV transmission among the general public 
included the following:
• 70% of respondents believed HIV can be transmitted 
through a bite.
• 24% believed HIV can be transmitted through kissing.
• 10% believed HIV can be transmitted through  
sharing a glass.
• 9% believed HIV can be transmitted through using  
a public toilet.
The authors also noted that over one-half of respondents 
believed that HIV can be transmitted through a blood 
transfusion. While theoretically possible, this is not a reality 
given the safeguards and screening used in Ireland. HIV 
Ireland suggested that this assumption may negatively affect 
experiences of health services.
Stigma and experiences of those living  
with HIV
The second survey found that stigma and the fear of stigma 
affect how people living with HIV experience their lives. 
Around two-thirds (61%) of people feared being rejected 
in a relationship and around half of this number (32%) had 
actually been rejected. Fifty-four per cent of respondents 
were single compared to 38% in the general population. 
The majority (61%) of people living with HIV had not disclosed 
their HIV status at some point, as they were afraid they would 
be judged or treated differently if they did. The stress that 
stigma can cause may explain why in the past year almost 
one in five (17%) respondents living with HIV had felt suicidal. 
More than one-third also reported having suffered from 
low self-esteem, anger, felt guilt or shame, and blamed 
themselves for their HIV status.
Other key findings among subjects living with HIV included 
the following: 
• 88% thought that some members of the general public 
believe that living with HIV is shameful.
• 35% agreed that some people do not want to associate 
with them, and 38% believed that some people think they 
deserve to have HIV.
• A majority believed that it was more stigmatising to have 
contracted HIV through sex (76%) and through injecting 
drug use (67%).
• 18% of respondents living with HIV have had their HIV 
status disclosed accidentally in a hospital setting.
Conclusions
The authors suggest that knowledge in the general population 
regarding HIV transmission is relatively good, potentially 
highlighting the work done in relation to HIV awareness-
raising in Ireland. Nevertheless, the study indicates that there 
is some room for improvement, in particular with regard to 
knowledge gaps and misperceptions among younger adults. 
Stigma still persists and affects the everyday lives of people 
living with HIV. While stigma is most sorely felt by the person 
immediately impacted upon, society at large is not immune 
from the effects resulting from HIV-related stigma, as it may 
reduce the likelihood of people getting tested. HIV Ireland 
hopes that this research will highlight these issues and 
provide data to support informed education, awareness-
raising, and effective policy development. 
Seán Millar
1 HIV Ireland (2017) HIV in Ireland 2017: Findings from the (1) 
National HIV Knowledge and Attitudes Survey 2017 and (2) People 
Living with HIV Stigma Survey 2017. Summary report. Dublin: HIV 
Ireland. http://www.drugsandalcohol.ie/27920/ 
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Public harms associated with  
street-based injecting
In late 2016, ALDP undertook a small project to document 
drug-related litter in the north inner city area of Dublin. Each 
afternoon a staff member walked two alternating routes 
in the area for two weeks; each route was covered every 
second day. In total, 57 separate instances of drug-related 
litter were identified, with over 1,750 individual pieces of 
litter being recorded. Litter was observed in a number of 
locations, but there were two ‘hot spots’2: the area bounded 
by Capel Street, Ormond Square, Mary’s Abbey and Ormond 
Quay, and that bounded by Jervis Street, Abbey Street 
Middle, O’Connell Street Lower and Ormond Quay.
Evidence of water for injection, citric acid and syringe caps 
were most frequently observed, and were recorded at 84%, 
82% and 78% instances, respectively. Syringes were observed 
at 53% and needles at 51% of the total instances. Faeces 
were recorded at over one-quarter of locations, highlighting 
the lack of public toilets in the area. 
Conclusions
The authors concluded that street-based injecting is an issue 
which requires attention in Dublin city centre, as the current 
situation perpetuates the use of high-risk environments by 
people who inject drugs as well as resulting in drug-related 
litter. Providing injecting drug users with the opportunity to 
access safer injecting spaces (such as supervised facilities) 
is a pragmatic approach to addressing this issue, as these 
services have repeatedly been shown to be effective in 
reducing harm, including overdose.5 Other interventions 
identified by ALDP included the following:
• Peer-led approaches to promoting safer disposal/return 
of drug-taking paraphernalia
•  Continued outreach to identify people engaging in 
street-based injecting
• The removal of barriers that hinder the ability of people 
engaged in street-based injecting from accessing the 
services they require.
Seán Millar
1 Department of Health (2017) Reducing harm, supporting 
recovery: a health-led response to drug and alcohol use in 
Ireland 2017—2025. Dublin: Department of Health.  
http://www.drugsandalcohol.ie/27603/ 
2 Keane M, Korovich M, Duffin T and Russell D (2017) At the dark 
end of the street: a report on street based injecting in Dublin 
city centre. Dublin: Ana Liffey Drug Project.  
http://www.drugsandalcohol.ie/27953/
3 Jennings CJ (2013) Re-establishing contact: a profile of clients 
attending the Health Promotion Unit — needle exchange at 
Merchants Quay Ireland. Dublin: Merchants Quay Ireland. 
http://www.drugsandalcohol.ie/19914/
4 Health Service Executive (2017) Frequently asked questions: 
supervised injecting facilities. Available online at http://hse.ie/
eng/about/Who/primarycare/socialinclusion/homelessness-
and-addiction/medically-supervised-injecting-centre/faq.html 
5 Potier C, Laprévote V, Dubois-Arber F, Cottencin O and 
Rolland B (2014) Supervised injection services: what has been 
demonstrated? A systematic literature review. Drug Alcohol 
Depend, 145: 48—68.
Street-based 
injecting in Dublin 
city centre
Ireland’s current drugs strategy emphasises a health-led 
response to drug use in Ireland.1 Consistent with this  
focus, a pilot supervised injecting facility (SIF) will open 
in 2018 in Dublin city centre. As Ireland moves towards 
implementation of the country’s first SIF, information with 
regard to public injecting among drug users in Dublin’s inner 
city is important. A 2017 report from the Ana Liffey Drug 
Project (ALDP) examined street-based injecting in Dublin  
city centre.2
Harms associated with street-based injecting
The report highlighted the harms associated with street-
based injecting. These include both private harms affecting 
individuals who are injecting and public harms which impinge 
on the community where injecting is occurring. Private 
harms include evidence suggesting that injecting in public 
places is conducive to hasty injecting, leading to safety and 
hygiene concerns. Public harms include drug-related litter 
in public and semi-public locations, thus creating a safety 
hazard to other individuals. 
Street-based injecting in Dublin city
A small number of studies have attempted to assess the 
prevalence of street-based injecting among drug users in 
Dublin. In 2013, Merchants Quay Ireland reported that 14% of 
subjects who used their needle and syringe exchange service 
generally injected in public places.3 More recently, ALDP 
asked individuals who use their Dublin services to take part 
in a survey. It was found that 28% of respondents reported 
injecting drug use in the last seven days; 18% of respondents 
reported mostly injecting on the street or in a service during 
this time.
It was noted that the issues facing this group are many and 
complex, with polydrug use and sharing of paraphernalia 
being of particular concern. In addition, 28% of respondents 
in the ALDP survey indicated having prior experience of 
overdose. The risk of fatal overdose is a constant reality 
among street-based drug injectors. As the Health Service 
Executive notes:
Public injecting is visually apparent in Dublin city 
centre through people using drugs and from drug-
related litter …. Between 2012 and 2014 there were 
25 drug-related deaths among people who inject 
drugs in public places in Dublin and 18 drug-related 
deaths among people who inject drugs who were in 
touch with homeless services in Dublin.4
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18 drug users have been prescribed naloxone, and an external 
evaluation concluded that the scheme was a success. MQI 
hopes that eventually all opiate drug users in Ireland will have 
access to this life-saving drug.
Family Support Group (FSG)
MQI offers one-to-one advice and support to family 
members on the realities of drug use and how they can best 
cope and provide optimum support to drug users. MQI also 
runs a Family Support Group (FSG), which meets every week 
and provides a forum where parents, as well as other close 
relatives and friends of drug users, are offered support and 
advice on a range of issues. Participants provide support 
for each other, and the group is continually open to new 
members. The weekly FSG is linked to the National Family 
Support Network, which offers an opportunity to raise 
issues at a national level. MQI’s FSG in Dublin worked with 25 
individuals throughout 2016.
Midlands Services
With support and funding from the Midland Regional 
Drug and Alcohol Task Force (MRDATF) and the HSE, MQI 
provides services in the four Midlands counties of Laois, 
Longford, Offaly and Westmeath. The MQI Family Support 
and Community Harm Reduction Team was established in 
late 2008 and provides dedicated outreach services for 
individuals actively using drugs. 
Merchants Quay 
Ireland annual 
review, 2016
Merchants Quay Ireland (MQI) is a national voluntary agency 
providing services for homeless people and drug users. There 
are 19 MQI locations in 12 counties in the Republic of Ireland. 
In September 2017, MQI published its annual review for 2016.1 
MQI aims to offer accessible, high-quality and effective 
services to people dealing with homelessness and addiction 
in order to meet their complex needs in a non-judgmental 
and compassionate way. This article highlights services 
provided by MQI to drug users in Ireland in 2016.
Open access services
Assertive Outreach Service (AOS)
In line with the MQI mission statement to reach out to the most 
vulnerable in society, this service aims to make contact with 
drug users not engaged with other services and to provide 
them with accessible support options. The geographical zone 
covered by the AOS is predominantly around each MQI location 
(Figure 1). Clients are assisted with clothing, food and drug 
treatment options. The service engaged with 116 individuals 
in specific casework, and with over 1,000 individuals on an 
informal support basis, throughout 2016.
Intensive Engagement Service (IES)
Many of the drug users who avail of MQI’s open access 
services are homeless and have financial and legal problems. 
The MQI morning service (10am to 1pm) is a one-to-one 
support function called the Intensive Engagement Service 
(IES). The IES provides support with accommodation; drug 
treatment; and training, medical, welfare and legal issues. 
In 2016, some 929 individuals availed of the IES, with 75% of 
people seeking help with accessing accommodation.
Health Promotion Unit 
This unit provides drug users with information about the 
risks associated with drug use and the means to minimise 
such risks. MQI offers drug users a pathway into treatment 
and the possibility of living a life without drugs. In the needle 
exchange and health promotion service, the main focus is 
on reducing the harms associated with injecting drug use; 
fostering the motivation to make positive change; giving 
advice on HIV, hepatitis B virus and hepatitis C virus infection 
prevention; and providing information on overdose and 
other risks. MQI also offers early referral to drug treatment 
services. In 2016, some 2,519 individuals used the service (a 
decrease of 6% on 2015), of which 421 were new clients.
As part of the MQI health promotion remit, a total of 2,139 
safer injecting workshops were undertaken with injecting 
drug users in 2016, an increase of 30% on 2015. There were 
25,603 needle exchange visits, a decrease of 1% on 2015.
Naloxone Demonstration Project 
Along with partners in the Health Service Executive (HSE), 
the National Family Support Network and the Ana Liffey Drug 
Project, MQI was front and centre in the national rollout of 
the Naloxone Demonstration Project in 2015. Naloxone is an 
antidote for opioid overdose that reverses the depressant 
effects of opiates such as heroin. To date, more than 400 
1  Dublin
2  Shelton Abbey, Co. Wicklow  
3  St Francis Farm, Co. Carlow 
4  Cork Prison 
5  Limerick Prison 
6  Co. Offaly 
7  Co. Westmeath 
8  Portlaoise, Co. Laois 
9  Co. Longford 
10  Castlerea Prison, Co. Roscommon  
11  Loughran House, Co. Cavan 
12  Leixlip, Co. Kildare
Source: MQI annual review, 2017
Figure 1: MQI locations in Ireland
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providing 2,309 harm reduction interventions. The service 
facilitated an average of 120 needle exchanges each month, 
operating in collaboration with the local pharmacy needle 
exchange scheme. MQI works on supporting clients in the 
‘pre-entry’ phase before admission to residential rehab and 
detox. Nine clients from the Midlands Region entered MQI 
residential drug treatment during the course of 2016.
Drug-free treatment services
St Francis Farm (SFF) Residential Rehabilitation and 
Detox Services
The SFF Rehabilitation Service offers a 13-bed therapeutic 
facility with a 14-week rehabilitation programme set on 
a working farm in Co. Carlow. At SFF, MQI provides a safe 
environment where service users can explore the reasons 
for their drug use, adjust to life without drugs, learn 
effective coping mechanisms, and make positive choices 
about their future. There were 53 clients admitted to the 
SFF Rehabilitation Service during 2016; 37 (70%) male and 16 
(30%) female. This represents a 4% increase in admissions 
compared with 2015.
The 10-bed residential detoxification service at SFF delivers 
methadone and combined methadone/benzodiazepine 
detoxes for both men and women. The detox activity 
programme includes individual care planning, therapeutic 
group work, psychoeducational workshops, fitness training, 
and farm-work activities. There were 72 clients admitted 
for detox service during 2016; 54 (75%) male and 18 (25%) 
female. This represents a 14% increase in admissions 
compared with 2015.
Prison-based services
MQI in partnership with the Irish Prison Service delivers a 
national prison-based Addiction Counselling Service (ACS) 
aimed at prisoners with drug and alcohol problems. This 
service provides structured assessments, one-to-one 
counselling, therapeutic group work, and multidisciplinary 
care, in addition to release-planning interventions with clearly 
defined treatment plans and goals. Services offered include: 
• Brief interventions
• Motivational interviewing and motivational  
enhancement therapy
• A 12-step facilitation programme
• Relapse prevention and overdose reduction
• Cognitive behavioural therapy 
• Harm reduction approaches
• Individual care planning and release planning
During 2016, some 2,624 prisoners accessed the ACS and 
the MQI team delivered 11,682 one-to-one counselling 
sessions and 3,033 group work attendances. The MQI 
ACS also coordinated and contributed to the delivery of 
a structured, multiagency eight-week Detox and Drug 
Treatment Programme (DTP) in the Mountjoy Prison Medical 
Unit. During 2016, the DTP assisted 80 prisoners in detoxing 
from methadone and benzodiazepines.
Seán Millar
1 Merchants Quay Ireland (2015) Merchants Quay  
Ireland: annual review 2016. Dublin: MQI.  
http://www.drugsandalcohol.ie/27910/ 
 
 
It also provides services focused on the needs of the families 
of active drug users. The Midlands team consists of MQI 
staff, Department of Social Protection participants, those on 
work placement, and volunteers working across these four 
Midlands counties.
In November 2016, MQI was awarded the contract to provide 
a community-based drug and alcohol treatment support 
service for individuals over 18 years of age and their families 
for the Midlands area. This service will complement and 
enhance existing statutory, community and voluntary services 
operating in the region in line with best international research 
and standards. This reorientation of services will ensure a 
harmonisation of treatment supports across the Midlands 
Region, thus providing a more equitable and accessible service 
to all. Since the award of the contract, MQI have been engaged 
in transitioning the existing service to the new model of service 
delivery as required by the service contract.
Midlands Rehabilitation and Aftercare Service
MQI, with the support of the MRDATF and the HSE, 
established the Rehabilitation and Aftercare Service in 
September 2010. The purpose of this service is to provide 
a range of rehabilitation and aftercare supports targeting 
clients from the region, including those exiting drug 
treatment and prison. This involves assisting clients in 
the process of regaining their capacity for a daily life free 
from the impact of problem drug use and enabling their 
reintegration into the community. MQI workers provide 
case management for clients with a view to ensuring that 
all individuals have their needs assessed and have the 
opportunity to participate in developing a care plan, offering 
a pathway towards rehabilitation. 
Workers also provide psychosocial support for persons 
leaving drug treatment or prison via one-to-one support and 
aftercare group work. This service worked with 75 individuals 
in 2016. The team liaised closely with interagency partners 
in order to address the underlying issues of addiction: 
accommodation, healthcare and abuse. Service users were 
both supported and challenged in terms of meeting their 
care plan goals and received one-to-one interventions and 
group support where required. There were 246 one-to-one 
sessions and 56 groups facilitated in 2016. 
Midlands Family Support Services
These services involve the provision of interventions that 
support families in coping with addiction-related issues. 
Such services often include counselling, guidance and 
advice. Under the drugs strategy, family support is seen as 
increasingly important in the areas of drug treatment and 
prevention. MQI works to proactively link people with other 
support or treatment services that may be relevant to their 
needs. In 2016, MQI provided interventions that supported 78 
family members in coping with addiction-related issues. 
Midlands Community Harm Reduction Services
MQI is aware that local people and organisations are often 
very concerned about the level of public and community 
harm associated with drug use in their communities, as well 
as the risks to which drug users may expose themselves. 
MQI seeks to empower drug users and their friends and 
family with all of the information to ensure that they keep 
themselves safe. In the Midlands Region, the MQI Community 
Harm Reduction Service worked with 165 clients during 2016, 
MQI annual review continued
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18 Self-harm and drug and alcohol use
Intentional drug overdose was the most common form of 
deliberate self-harm reported in 2016, occurring in 7,646 
(67%) of episodes. As observed in 2015, overdose rates were 
higher among women (72%) than among men (59%). Minor 
tranquillisers and antidepressants/mood stabilisers were 
involved in 35% and 19% of drug overdose acts, respectively. 
In total, 32% of male and 47% of female overdose cases 
involved analgesic drugs, most commonly paracetamol, 
which was involved in 30% of all drug overdose acts. In 69% 
of cases, the total number of tablets taken was known, with 
an average of 29 tablets taken in episodes of self-harm that 
involved a drug overdose.
There was no increase in the number of presentations 
involving street drugs (cannabis, ecstasy and cocaine) 
compared to 2015 (n=547). Nevertheless, the 2015/16 levels 
are the highest recorded since 2008 and the second highest 
ever recorded by the registry. Alcohol was involved in 31% 
of all self-harm presentations, and was significantly more 
often involved in male episodes of self-harm than females 
(34% vs 29%, respectively). The authors reported that, as in 
previous years, alcohol continued to be one of the factors 
associated with the higher rate of self-harm presentations 
on Sundays, Mondays and public holidays, and in the hours 
around midnight. 
The authors concluded that these findings underline the 
need for ongoing efforts: 
• To reduce access to minor tranquillisers and other 
frequently used drugs, including paracetamol
• To intensify national strategies to increase awareness  
of mental health issues 
• To intensify further strategies to reduce access  
to alcohol.
Seán Millar
1 Griffin E, Arensman E, Corcoran P, Williamson E and  
Perry IJ (2017) National Self-Harm Registry Ireland annual 
report 2016. Cork: National Suicide Research Foundation.  
http://www.drugsandalcohol.ie/27916/
National Self-Harm 
Registry annual 
report, 2016
The 15th annual report from National Self-Harm Registry 
Ireland was published in late 2017.1 The report contains 
information relating to every recorded presentation 
of deliberate self-harm to acute hospital emergency 
departments in Ireland in 2016 and complete national 
coverage of cases treated. All individuals who were alive on 
admission to hospital following deliberate self-harm were 
included, along with the methods of deliberate self-harm 
that were used. Accidental overdoses of medication, street 
drugs or alcohol were not included. 
Rates of self-harm
There were 11,485 recorded presentations of deliberate 
self-harm in 2016, involving 8,909 individuals. Taking the 
population into account, the age standardised rate of 
individuals presenting to hospital in the Republic of Ireland 
following self-harm was 206 per 100,000 population. This 
is similar to the rate recorded in 2015 (204 per 100,000 
population). In recent years, there have been successive 
decreases in the self-harm rate between 2011 and 2013. 
Nevertheless, the rate in 2016 was still 10% higher than in 
2007, the year before the economic recession (Figure 1).
In 2016, the national male rate of self-harm was 184 per 
100,000 population, 1% lower than in 2015. The female rate 
was 229 per 100,000 population, which was 3% higher than 
in 2015. Since 2007, the male and female rates of self-harm 
have increased by 14% and 7%, respectively. With regard to 
age, the peak rate for men was in the 20—24-age group at 
516 per 100,000 population. The peak rate for women was 
among 15—19-year-olds at 763 per 100,000 population. 
Figure 1: Person-based rate of deliberate self-harm from 2002 to 2016 by gender 
Source: National Suicide Research Foundation, 2017
‘All’ in the legend refers to the rate for both men and women per 100,000 population.
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Results 
An adjusted Cox regression model indicated that participants 
who opted for outpatient aftercare treatment had a lapse/
relapse rate that was 52% higher than the inpatient aftercare 
group (hazard ratio [HR] 1.52, 95% confidence interval [CI] 
0.75–3.08), although this difference was not statistically 
significant. Time to first use of drugs was considerably 
shorter for the no formal aftercare group (HR 7.68, 95%  
CI 4.30–13.73) when compared to those who received 
inpatient aftercare, highlighting that any aftercare is 
significantly better than no aftercare. Furthermore,  
patients who attended any form of aftercare were more 
likely than the no formal aftercare group to be abstinent 
at nine-month follow-up. Abstinence rates for outpatient 
aftercare and inpatient aftercare were found to be equal 
after nine months.
Conclusions
The authors concluded that patients who opt for aftercare 
post-detoxification have significantly better outcomes 
at follow-up when compared to no formal aftercare. In 
addition, the marginal benefit that the study demonstrated 
for inpatient aftercare over outpatient aftercare should be 
taken into account when planning services, as it is almost as 
effective and cheaper to provide.
Seán Millar
1 Ivers JH, Zgaga L, Sweeney B, Keenan E, Darker C, et al. (2017) A 
naturalistic longitudinal analysis of post‐detoxification outcomes 
in opioid‐dependent patients. Drug Alcohol Rev [forthcoming].
2 Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, Cooke R 
(2005) The characteristics of heroin users entering treatment: 
findings from the Australian treatment outcome study (ATOS). 
Drug Alcohol Rev, 24(5): 411–18.
3 Teesson M, Ross J, Darke S, Lynskey M, Ali R, Ritter A, Cooke R 
(2006) One year outcomes for heroin dependence: findings 
from the Australian Treatment Outcome Study (ATOS). Drug 
Alcohol Depend, 83(2): 174–80.
4 Teesson M, Mills K, Ross J, Darke S, Williamson A, Havard A 
(2008) The impact of treatment on 3 years’ outcome for heroin 
dependence: findings from the Australian Treatment Outcome 
Study (ATOS). Addiction, 103(1): 80–88. 
Post-detoxification 
outcomes in opioid-
dependent patients
There are currently in excess of 10,000 opioid-dependent 
patients receiving substitution therapy in Ireland,1 with 
the majority of those attending detoxification receiving 
methadone. Given the weak evidence base with regard to 
the efficacy of detoxification, many clinicians opt to continue 
substitute-prescribing or may even dissuade opioid-
dependent persons from detoxifying.
A small number of international studies have examined 
problem drug users in detoxification treatment. Follow-up 
studies have noted discernible reductions in heroin use as 
well as significant reductions in criminality, psychopathology, 
and injection-related health problems following treatment 
exposure.2,3,4 Nevertheless, the majority of these studies 
are limited to two time points and fail to take into account 
longitudinal changes. Importantly, no studies to date have 
focused on aftercare post-detoxification. 
Recent research conducted in Ireland examined outcomes in 
a cohort of opioid-dependent patients post-detoxification.1 
In this study, which has been published in the journal Drug 
and Alcohol Review, patients completing detoxification in 
the three major Drug Dependency Units in Ireland during a 
14-month period were examined (n=143). Subjects opting 
for one of the three pathways post-detoxification (inpatient 
aftercare, outpatient aftercare, or no formal aftercare) were 
assessed in the final week of detoxification and followed up 
after three, six and nine months. The primary outcome was 
abstinence following detoxification.
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18 Findings
Methadone was implicated in 182 poisoning deaths that 
occurred during the study period. Just over half of the 
deaths were among persons aged 34 years or less (54%), and 
the majority of deaths were among males (78%). During the 
two-year period, more people died off OAT treatment (61%) 
than on OAT treatment (39%). 
The study further found that a large number of methadone-
related deaths were among persons previously treated 
for substance dependency, and many involved more 
than one substance. It was not possible to identify 
how many of those dying of fatal overdose were opioid 
dependent or were using diverted methadone for 
recreational or self-medicating purposes, nor was it 
clear how many had previous contact with OAT providers. 
Nonetheless, the findings suggest the targeting of overdose 
prevention interventions (such as overdose recognition, 
cardiopulmonary resuscitation, and naloxone) to those 
accessing all types of drug treatment services and not just 
those offering OAT. Over one-third of the fatal overdoses 
involving methadone were in patients registered for OAT, 
highlighting the unique position of OAT providers in risk 
assessment and overdose prevention. The finding that a 
high number of deaths occurred in a private dwelling and 
in the presence of others suggests that family and peers 
should also be involved in overdose prevention initiatives. 
Limitations
A key limitation of the study is that the number of deaths 
off treatment may have been underestimated, as patients 
are not removed from the CTL until 28 days after treatment 
ceases. A further limitation is that it was not possible to 
differentiate between groups not registered for OAT, in 
particular those on waiting lists for OAT; those who just 
completed treatment; and those on buprenorphine. The 
study was also limited by the incomplete data for some 
variables, resulting from missing data in the original data 
sources accessible to the NDRDI. Access to a greater number 
of data sources would ensure more comprehensive data 
that could further inform the development and targeting of 
overdose prevention. The authors conclude that knowledge 
of patient characteristics, along with improved risk 
assessment and OAT retention strategies, can be used to 
inform any future national drug overdose plan.
Cathy Kelleher
1 Van Hout MC, Crowley D, Collins C, Barry A, Lyons S and Delargy 
I (2017) Characteristics of methadone-related overdose deaths 
and comparisons between those dying on and off opioid agonist 
treatment (OAT): a national cohort study. Heroin Addict Relat 
Clin Probl [Early online]. http://www.drugsandalcohol.ie/27568/ 
2 Cousins G, Boland F, Courtney B, Barry J, Lyons S and Fahey 
T (2016) Risk of mortality on and off methadone substitution 
treatment in primary care: a national cohort study. Addiction, 
111(1): 73—82. http://www.drugsandalcohol.ie/24374/ 
Characteristics of 
methadone-related 
overdose deaths 
and comparisons 
between those dying 
on and off opioid 
agonist treatment
A national cohort study published online in Heroin 
Addiction and Related Clinical Problems aimed to describe 
characteristics of methadone-related overdose deaths 
in Ireland and to compare deaths occurring among those 
registered for opioid agonist treatment (OAT) with deaths 
among those not registered.1 OAT involves the use of drugs 
such as methadone or buprenorphine to reduce cravings and 
withdrawal symptoms among those addicted to opioids such 
as heroin. 
It is well established that OAT, including methadone 
substitution therapy, can reduce deaths among problem 
opiate users. However, OAT is also associated with a risk of 
accidental overdose, as patients can experience lowered 
tolerance for opioids following a period of abstinence. 
Individuals completing detoxification, leaving prison, or 
exiting OAT may therefore be especially vulnerable to 
accidental death by overdose. Previous research in Ireland 
found that people treated with methadone were nearly four 
times more likely to die in periods off treatment than in 
periods on treatment.2
Methodology
The current study drew on the Irish National Drug-Related 
Deaths Index (NDRDI) to identify persons who had died 
of a drug overdose involving methadone between 2012 
and 2013. The NDRDI is an epidemiological database that 
draws on four sources — the Coroner Service, the Hospital 
Inpatients Enquiry Scheme, the Central Treatment List (CTL), 
and the General Mortality Register through the Central 
Statistics Office — to provide comprehensive data on drug-
related deaths. The NDRDI classifies drug-related deaths 
as poisonings or non-poisonings (fatal overdoses), where 
‘poisonings’ are deaths resulting from the toxic effects of 
the consumption of a drug(s) and/or other substances, and 
excludes adverse reactions to prescribed medications. 
Included in the current study were methadone-related 
poisoning deaths. 
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resources. Being able to quantify a government’s drug-
related public expenditure is a key step in carrying out any 
economic evaluation of its drug policy interventions. 
In this economic climate, more than ever, 
policymakers and service planners require data  
and information on the capacity, performance  
and costs of national treatment systems in order  
to support investment decisions and to make sound 
policy choices.2 (p. 5)
This move towards improving understanding of drug-
related public expenditure and its accurate measurement 
is reflected in European Union (EU) policy. One of the 15 
overarching indicators for measuring the achievements of 
the EU action plan on drugs (2017—2020) includes developing 
national evaluations and public expenditure estimates.3 
Despite this, it is a methodological area in which knowledge 
is described as ‘sparse’ (p. 5).1 To address this gap, the 
European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) has been given the role of ‘developing analytical 
instruments to better assess the effectiveness and impact of 
drug policy using a number of tools including the analysis of 
public expenditure’ (p. 5).2 These reports were commissioned 
as part of this effort. 
Supply reduction public expenditure
Public expenditure on supply reduction policies provides 
an overview of the key concepts involved in estimating 
public expenditure. While focused on supply reduction, the 
report offers a very useful introduction to the field of drug-
related public expenditure more generally. It explains in an 
accessible way the core concepts involved and outlines the 
key steps in cost estimation and analysis.4 For example, it 
describes the international classifications for the functions 
of government used in this field (Reuters and COFOG), 
as well as a detailed description of the characteristics of 
labelled and unlabelled expenditure. 
Supply reduction initiatives are defined as those comprising 
‘the whole system of laws, regulatory measures, courses 
of action and funding priorities concerning illicit drugs put 
into effect by a government or its representatives’ (p. 8)1 
(e.g. police and customs officers and judges). The report 
outlines examples of models for estimating unlabelled supply 
reduction activity in related sectors — the police, customs 
and prison services as well as court systems. A sample of 
national studies which have applied models for estimating 
labelled and unlabelled expenditure on supply reduction are 
also described. 
The report concludes with a set of recommendations that 
focus on improving the quality of data and methodological 
approaches to analysis. There is a particular focus on the 
need for consistency in classification of the data and for 
partnership working with all relevant stakeholders in the field.
Drug treatment expenditure 
Drug treatment expenditure: a methodological overview is a 
much more substantial report than that on supply reduction 
policies. It gathers together detailed methodological papers 
from across the globe to provide an overview of ‘the current 
state of the art in this field’ (p. 179).2 While it indicates a 
growing interest and level of research activity on the topic, 
the authors describe it as still being in its ‘infancy’ (p. 179).2 
The report highlights the methodological complexities of 
the topic, with much discussion on the challenges faced 
POLICY AND LEGISLATION 
Exploring drug-
related public 
expenditure 
Two reports have been published that explore drug-related 
public expenditure and the methodological challenges faced 
in estimating its value: Public expenditure on supply reduction 
policies1 was published in May 2017, while Drug treatment 
expenditure: a methodological overview2 was published in 
October 2017. The reports overlap extensively in terms of 
their descriptions of what drug-related public expenditure 
is, the context in which they were commissioned, and the 
overall messages from their findings. 
What is drug-related public expenditure? 
Public expenditure is defined as ‘the value of goods and 
services purchased or utilised by the general government in 
order to perform each of its functions’ (p. 15).2 This includes 
any drug-related spending across the various functions of 
government, including healthcare, justice, public order, 
education, and social protection. Broadly speaking, drug-
related public expenditure is described as ‘labelled’ or 
‘unlabelled’. Labelled drug-related expenditure is 
the ex-ante planned public expenditure made by 
general government in the budget that reflects the 
public and voluntary commitment of a country in 
the field of drugs. In addition, it is any expenditure 
identified as drug-related in public accountancy 
documents.1 (p. 23)
In the Irish context, this would include budget allocations  
for the Health Service Executive (HSE) addiction services  
and treatment services in prison, for example. Unlabelled  
drug-related expenditure is
the non-planned or non-publicly announced  
ex-post public expenditure incurred by the general 
government in tackling drugs that is not identified as 
drug-related in the budget.1 (p. 24)
This would include, for example, the cost incurred for the 
imprisonment of people for drug-related offences. Total 
drug-related public expenditure is the sum of both labelled 
and unlabelled expenditure.
Context of reports
Internationally, there are growing demands on governments 
to support effective responses to problematic drug use. 
However, simultaneously, budgets for both supply and 
demand reduction activities have tended to decrease as a 
consequence of austerity measures implemented following 
the 2008 recession. This has contributed to a context where 
‘ensuring value for money in public investment [is] high up 
on the political agenda’ (p. 179).2 It is within this context that 
there is a need for governments to carry out rigorous policy 
evaluations that include an economic assessment. This will 
support better decision-making about where to allocate 
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study, including the operational definition applied in 
estimates. This should help to clarify the scope and 
objective of estimates.
• Develop a map of treatment provision and funding flows. 
This exercise will help identify missing data, minimise the 
risk of double counting and facilitate assessment of the 
coverage of estimates.
• Analyse all levels of government activity, budgets  
and/or fiscal-end accountancy reports to identify 
labelled expenditure on drug treatment, as 
responsibility for financing drug treatment can lie  
with multiple actors (p. 188).2
Key messages
While exploring different aspects of drug policy, there was 
much overlap in the findings of these reports. Both argue 
the importance of being able to calculate drug-related 
public expenditure if policy-makers are to be able to make 
decisions about the most cost-efficient approaches to 
addressing problematic drug use. They found numerous 
challenges to collecting and comparing drug-related 
expenditure across jurisdictions, with different political 
structures and government accounting systems. An absence 
of commonly agreed definitions and methodologies, a lack of 
comparable datasets, and uncertainty about which economic 
models to use, were identified in both reports as barriers 
to the rapid development of policy evaluation and cost-
effective analysis. 
Lucy Dillon
1 Bretteville-Jensen AL, Costa Storti C, Kattau T, Mikulic S, 
Trigueiros F, Papamalis F, et al. (EMCDDA) (2017) Public 
expenditure on supply reduction policies. Brussels: Council of 
Europe. http://www.drugsandalcohol.ie/27458/
2 European Monitoring Centre for Drugs and Drug Addiction 
(2017) Drug treatment expenditure: a methodological overview, 
EMCDDA Insights 24. Luxembourg: Publications Office of the 
European Union. http://www.drugsandalcohol.ie/28010/ 
3 European Commission (2017) EU action plan on drugs  
2017–2020. Brussels: Council of the European Union.  
http://www.drugsandalcohol.ie/27680/ 
4 Another Drugnet article also explains the basic concepts of 
drug-related public expenditure in some detail. See Pike B 
(2008) Understanding drug-related public expenditure. Drugnet 
Ireland, 27: 23—24. http://www.drugsandalcohol.ie/12125/ 
in carrying out this work. It highlights the need for more 
agreement on common definitions and improved data 
sources. The main body of the report is broken down into 
five sections, each of which focuses on broadly different 
methodological approaches taken on the topic. 
• ‘Towards an overall estimate of public expenditure on 
drug treatment’ describes the approach taken by a 
team in Australia to provide an overall estimate of drug 
treatment expenditure. It highlights the methodological 
challenges in doing so, including being unable to isolate 
expenditure on treatment for alcohol misuse from that 
on drug treatment. 
• The second and third sections present the methods used 
when focusing on labelled (three studies) or unlabelled 
expenditure (five studies), respectively.
• ‘Other tools to measure the costs of drug-related harm’ 
contains two studies. The first describes a ‘calculator’ 
developed by Public Health England which can be used 
by local authorities in their appraisal of their spending 
on drug-related interventions. The second explores 
the issue of cost sensitivity in relation to the delivery of 
services across teams – how much would costs increase 
if established drug treatment teams were to increase 
their activity? 
• The fifth section is about ‘contextualising costs’. It 
presents the findings of three diverse studies which show 
that public expenditure on drug treatment is only part 
of the picture when exploring costs. They highlight the 
importance of placing public spending estimates in the 
right context. It addresses questions such as how should 
estimates on drug treatment vary if a significant amount 
of costs are borne by the private sector.
The final substantive section of the report identifies the main 
methodological commonalities and considerations from 
across the studies. The authors conclude with a set of 10 
‘good practices’ (p. 188)2 that they suggest could be used to 
improve estimates of public expenditure on drug treatment. 
These include to:
• Ensure that clearly defined aims and objectives are 
developed for each exercise, and note that these may 
differ from case to case.
Drug-related public expenditure 
continued
Ireland, Irishness and 
alcohol: changing  
the relationship 
In November 2017, over 150 people attended two timely 
events in Letterkenny, Co. Donegal as part of the fourth 
National Conference of the Alcohol Forum, which aimed to 
challenge the narrative around the cultural inevitability of 
alcohol harm in Ireland. 
The conference ‘Ireland, Irishness and Alcohol: Changing 
the Relationship’ explored the historical, social and 
cultural factors that have shaped and maintained Ireland’s 
problematic relationship with alcohol and examined how 
notions of culture are exploited by the global alcohol 
industry. The conference offered new theoretical and policy 
perspectives for understanding, challenging and changing 
the Irish relationship with harmful drinking. It also brought 
together diverse speakers from Ireland and the USA and from 
a range of different disciplines. 
The opening event was a screening of the Irish-American film 
Emerald City in the Regional Cultural Centre, Letterkenny. 
The film explored the struggles with alcohol, mental health 
and identity among a group of Irish immigrant construction 
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responding to local needs, all plans are underpinned by a 
clear public health approach, including actions on issues 
such as licensing, advertising, availability and underage 
supply. In the plenary discussion, Dr Jernigan commended 
the work of the Community Action on Alcohol Programme 
and its clear focus on and understanding of a public health 
approach. Professor Frank Murray and Senator Frances Black 
joined the afternoon plenary session, with both calling for 
increased public support for the Public Health (Alcohol) 
Bill 2015. Marian Harkin MEP, who chaired the afternoon 
discussion, welcomed the way in which the conference had 
approached the issues: 
It is very clear from today that we are talking about 
the regulation of the alcohol industry and not about 
regulating the individual choices that people make. 
This is an important way of having the conversation 
and I congratulate you all on a brilliant event. 
Tackling alcohol harm locally and globally will require action 
from a wide range of sectors and individuals. Involving film-
makers, historians, social workers, public health experts and 
political representatives, the conference offered a broader 
approach to the issues, moving beyond health and enabling 
us to explore a variety of different perspectives. The formula, 
based on the feedback from many of those who participated 
on the day, worked.
Paula Leonard 
workers in 1990’s New York. The event was attended by  
film-maker Colin Broderick, who had travelled from the 
US to be part of the evening. A frank and honest panel 
discussion, exploring the impact of alcohol on families, was 
chaired by Denis Bradley, who was joined by Colin, Donna 
Butler from the Alcohol Forum’s Families Matter programme 
and Rachel Reisman from the Irish International Immigrant 
Center in Boston. 
A day-long conference was held the next day in Letterkenny 
Institute of Technology. Setting the context and providing 
information on the level of alcohol harm in Ireland, Dr Jean 
Long of the Health Research Board was the keynote speaker. 
She provided an analysis of the relationship between 
patterns of consumption and levels of harm in a population, 
highlighting the fact that in the 32-year period, 1984 to 
2016, alcohol consumption in Ireland trebled and, despite 
an overall decrease since 2001, consumption in 2016 rose by 
500 ml per person to 11.5 litres. 
There followed presentations by historian Dr Gearóid Ó 
Tuathaigh, former dean of arts in NUI Galway, and social 
worker Rachel Reisman from the Irish International 
Immigrant Center. Dr Ó Tuathaigh explored some of the 
historical forces that shaped the construction of the 
negative Irish stereotype, including the description of the 
‘native’ and ‘Gaelic’ as lesser, uncivilised and drunken 
at various points throughout a history of colonialism. He 
concluded that while stereotypes can be persistent they are 
by no means fixed or inevitable. A member of the Council of 
State, he also spoke about the potential power of symbolic 
leadership, referring to the entertaining of foreign dignitaries 
and heads of state at the Guinness Store House. With a 
rich history and heritage, there are vast opportunities 
for Government to show leadership on this issue. Rachel 
Reisman further emphasised the power of leadership in 
changing attitudes and breaking the stigma, pointing to 
the huge support there has been for Boston Mayor Marty 
Walsh in making public his own recovery journey from 
alcohol. The chair for the morning session, RTÉ journalist 
Tommie Gorman, highlighted the power of including a 
diaspora perspective: ‘I think it’s a really clever programme; 
sometimes it’s useful to look at ourselves from the outside.’ 
The afternoon continued with the interdisciplinary 
approach, opening with global alcohol marketing expert Dr 
David Jernigan, former adviser to both the World Health 
Organization and the World Bank. This was followed by a 
presentation of the work of the National Community Action 
on Alcohol by Paula Leonard from the Alcohol Forum. Paula 
highlighted the growth in the numbers of communities 
which now have developed or are currently developing local 
community action on alcohol plans. Although diverse and 
About the Alcohol Forum
The Alcohol Forum supports children, families, individuals, 
and communities affected by alcohol. Founded in Donegal 
in 2007, the charity has a national programme aimed at 
delivering its vision of an Ireland where every child, family 
and community is free from the harmful effects of alcohol. 
Its work is an evidence-informed response to the harm 
caused by alcohol misuse in communities across Ireland. 
Since the Alcohol Forum’s formation as an interagency 
forum, the work of the charity has been underpinned by an 
understanding that partnership working and wide sectoral 
and community engagement are required for any real 
change to be achieved in reducing alcohol harm in Ireland. 
Alcohol Forum, Unit B9 Enterprise Fund Business Centre, 
Ballyraine, Letterkenny, Co. Donegal 
For more information, contact Mariclare Gallagher at 
mariclare@alcoholforum.org or phone 074 912 5596.  
Website: www.alcoholforum.org
Kieran Doherty of the CEO, the Alcohol Forum, 
with other members of the forum, conference 
speakers and delegates at ‘Ireland, Irishness and 
Alcohol: Changing the Relationship’ in Letterkenny 
in November 2017
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18 • A highlight of some key issues, for example, developing 
areas such as e-health, and links to more detailed 
information on these topics.
• A platform for ongoing work in the health and social 
responses area. 
The report is part of a package which includes a range of 
additional materials online that will be added to and regularly 
updated.3 
These policy and practice briefings provide: 
• A summary of the main issues, response options, and 
some information about what is happening in Europe
• A summary of the evidence for responses in that 
particular area
• The key implications for policy and practice
• Links to further resources 
The webpage provides links to a range of background papers 
that were commissioned to help in drafting the report. These 
include an evidence review summary, and others dealing with 
a range of ‘hot topics’, such as addressing the needs of the 
ageing cohort of opiate users seen in many countries, drug-
checking services, e-health, and how to use behavioural 
insights to improve the effectiveness of responses.
The best practice links include:
• The Best Practice Portal evidence registry where you can 
search for evidence on particular topics; and
• The Xchange registry, which provides information on 
individual programmes and the people and places in 
which they have been used. This is currently mainly 
prevention programmes but will be expanded to include 
other types of interventions in the future.
 
This report is not in the traditional report style and adopts a 
new format inspired by the idea of a travel guide. It is focused 
on how to respond to different drug problems rather than 
giving details about the extent and nature of drug problems. 
This information is covered in the European drug report 2017.4
It is action-orientated rather than in textbook style. It is, 
inevitably, a brief overview of each topic, but easy to read 
and providing links to more detailed information.
RESPONSES 
EMCDDA publishes 
guide on evidence-
based responses to 
drug problems
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) aims to provide a comprehensive picture 
of the drug phenomenon in Europe and the responses to 
drug problems to help policy-makers and practitioners 
develop and implement effective policies and interventions. 
The recently published Health and social responses to drug 
problems: a European guide1 forms an important part of 
this overall picture and provides practitioners with a useful 
roadmap for managing interventions.
Responses can be defined as ‘any actions or interventions 
that are undertaken to address the negative consequences 
associated with the illicit drugs phenomenon’ (p. 9). 
Responses on the supply side are covered in the EU  
drug markets report.2
The authors of the guide were faced with a number of 
challenges. Within Europe the drug situation is very varied, 
many different drugs are being used, the contexts of this 
usage vary, and there are different stages of development 
of drug problems in different areas. So, there is no simple 
blueprint for the responses that should be put in place. 
Further, drug problems can change rapidly and vary over time, 
so a regular review of the policies and responses is necessary.
To address these challenges the report provides:
• A way of thinking about how to respond to drug problems 
in a particular country or local area and identify what 
is needed and likely to be appropriate to a particular 
situation.
• A brief overview of current knowledge that attempts to 
answer what can be done, what works, and what we know 
about what is currently being provided in Europe.
Problem 
denition
Response 
selection Implementation
Assessment 
of outcomes 
achieved
Response
chosen
Aims and 
outcomes sought
Knowledge base
Contextual factors and inuences
Figure 1: The three broad stages of developing responses to drug problems
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awareness of overdose risk situations and behaviour, such 
as the dangers of combined use of central nervous system 
depressants — opioids, alcohol and benzodiazepines; and 
training potential bystanders to detect overdose signs and to 
respond accordingly. These include drug users, peers, family, 
healthcare and social services staff, and the police.
Another aspect is improving prison-to-the-community 
throughcare. This is a period of particularly high risk of 
overdose deaths. This section also looks at barriers to the 
establishment of drug consumption rooms in areas with lots 
of street injecting and addressing legal obstacles to calling 
the police (Good Samaritan laws).
Chapter 3 looks at responses from the perspective of 
different target groups.
As an example, one section of this chapter looks at 
responses in nightlife, festivals and other recreational 
settings. Here there are a range of response options, and 
multi-component, multiagency approaches appear most 
successful. These will often target alcohol as well as drug use
These responses include:
• Providing information and education to drug users to 
reduce harms.
• Environmental strategies, such as regulating venues, e.g. 
limiting happy hour promotions and other factors that 
promote dangerous consumption patterns; providing 
chill-out rooms, free water and cheap soft drinks; 
training of staff and ensuring first aid and emergency 
responses are available.
• Establishing drug-checking services that can provide 
alerts, advice and brief interventions to reduce harms  
as well as information for early warning systems and 
market monitoring.
There is increasing interest across Europe in establishing 
drug-checking services, for which there are many different 
models. One background paper provides more detail on 
these (including the map in Figure 3). 
The guide is intended as a reference document with clear 
signposting, and uses boxes and colour coding to make 
it easier to scan. Boxes and sections have different icons 
depending on the type of material they contain. 
The report has five main chapters, topped and tailed 
by an introduction and concluding remarks. Chapter 1 
discusses the different factors that need to be considered 
in developing responses to drug problems. Chapters 2, 3 
and 4 consider what we know about responding to different 
drug problems, viewed from three different perspectives: 
responding to problems arising from use of different drugs  
or types of use; responding to the needs of particular groups 
of individuals; and, responding in different settings. Chapter 
5 looks at ways of supporting the successful implementation 
of responses.
Chapter 1 presents a way of thinking about the whole 
process of responding to drug problems. 
An example from this chapter is tackling opioid-related 
deaths, which are increasing in a number of countries. The 
chapter highlights a range of response options that seek to 
reduce the risk of death:
• At the bottom of the ‘pyramid’ are wider public health 
interventions that aim to make opioid users less 
vulnerable to overdose.
• In the middle are interventions that make it less likely 
that people who use opioids will overdose — retaining 
them in opioid substitution treatment, assessing their 
risk of overdose, and raising their awareness of the 
dangers of overdose. 
• Finally, at the top, are interventions that can prevent 
deaths when overdoses do occur — the widespread 
availability of naloxone, which can reverse overdoses, and 
supervised drug consumption rooms in which immediate 
first aid can be given if overdose does occur.
The implications for policy and practice highlight the 
importance of improving provision of the programmes 
already mentioned. For example: improving drug users’ 
Outreach
 and
low-threshold 
services
Accessible
services
Retention
in opioid
substitution
treatment
Reduce drug use 
and injecting
Overdose 
awareness 
Knowledge of risk 
and safer use 
Overdose
risk
assessments 
In treatment 
facilities and 
prisons
Supervised 
drug
consumption
Immediate rst-aid 
in drug emergencies
Take-home
naloxone
programmes
Improved bystander 
response
Enabling
environment
Removing
barriers to service 
provision
Empowerment 
of drug users
Enabling drug 
users to protect 
themselves
Public health
approach
Recognition of 
wider impact
Reducing 
vulnerability
Reducing risk of
overdose
Reducing fatal
outcome of overdose
Figure 2: Interventions to reduce the risk to opiod-related deaths
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18 The final section is on the importance of monitoring and 
evaluation to promote learning from experience and 
continuous improvement in outcomes. 
Brian Galvin
1 European Monitoring Centre for Drugs and Drug Addiction. 
(2017) Health and social responses to drug problems: a European 
guide. Luxembourg: Publications Office of the European Union. 
http://www.drugsandalcohol.ie/28040/ 
2 European Monitoring Centre for Drugs and Drug Addiction 
and Europol. (2016) EU drug markets report: in-depth analysis. 
Luxembourg: Publications Office of the European Union.  
http://www.drugsandalcohol.ie/25357/ 
3 The report and the other materials can be accessed through 
a webpage on the EMCDDA website: http://www.emcdda.
europa.eu/responses-guide. From there you can download an 
electronic version of the guide as a PDF (an e-book format will 
be available in the future). From the second tab, you can get 
access to policy and practice briefings, covering each of the 
topics in the guide. From the fourth tab, there are links to a 
range of further resources, including best practice databases, 
topic pages, and more detailed reports related to the topics in 
the guide. 
4 European Monitoring Centre for Drugs and Drug Addiction. 
(2017) European drug report 2017 trends and developments. 
Luxembourg: Publications Office of the European Union.  
Available online at http://www.emcdda.europa.eu/edr2017_en 
Chapter 5 focuses on ways to support successful 
implementation
An evidence-based programme will only be successful if it 
is well implemented. The first section of this chapter looks 
at ways of encouraging the use of evidence in practice, 
and it considers the challenge of transferring programmes 
into different cultural contexts, how quality standards and 
guidelines can be used to improve the effectiveness of 
services, and the importance of sharing best practice.
It highlights as implications for policy and practice the 
potential benefits of:
• Implementing the European minimum quality standards 
for demand reduction and the establishment of national 
standards and guidelines; and
• The further development of best practice exchange 
websites and other e-health support tools.
Section 5.2 focuses on the importance of supporting the 
people and organisations involved and considering systems 
and partnerships in order to promote effective delivery. It 
highlights the importance of training and staff development, 
service user and community involvement, promoting 
multiagency working and taking a systems-wide perspective 
of responses in order to, as we would say, make the whole 
greater than the sum of its parts.
EMCDDA guide to health 
responses continued
Figure 3. Drug checking sites in Europe
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Impact of NFSN
Susan Scally from the Drugs Policy Unit outlined the effect 
that the NFSN has had on shaping the national drugs 
strategy (2017—2025). Its family and community insight fed 
the extensive consultation process in forming the national 
drugs strategy. Next, Anna Quigley of CityWide took us on a 
whistle-stop tour of the organisation and their partnership 
with the NFSN from the 1980s — where there was much 
stigmatisation around drug misuse and where the focus lay 
with politicians and policy-makers — through to today, where 
communities and families have a clear input into policies and 
procedures governing drug misuse. Anna spoke warmly of 
the first service of commemoration organised by the NFSN 
in 2000, which became a catalyst for their subsequent work. 
She spoke of the ardent appeal for more accurate reporting 
of drug-related deaths, which they knew were being under-
reported, and which eventually contributed to the creation 
of the National Drug-Related Deaths Index (NDRDI).4 She 
spoke of how the NFSN contributed to research carried out 
by the National Advisory Committee on Drugs and Alcohol 
on the impact of drug misuse in families.5 In addition, its 
contributions to the move towards the decriminalisation 
of narcotics in 2015 for personal use was another long 
fought-for appeal by the NFSN to support people and not 
punish them. National conferences and working with various 
organisations to publish reports are among the many strings 
to its bow.
Tony Hickey, former Assistant Garda Commissioner and 
board member of the NFSN, had the audience nodding in 
agreement and in laughter, and sometimes gasping, as  
he told anecdotes of his time working as a guard on the 
streets of Dublin. He recounted how Ireland could be a 
judgemental society but that families have worked hard  
to change attitudes. 
Launch of report
The event was also an occasion to launch the report,  
Valuing family support: a social return on investment  
report on the value of family support for families coping  
with addiction issues.6 
Ten-year celebration 
of National Family 
Support Network
The National Family Support Network (NFSN)1 is a self-help 
organisation supporting the development of family support 
groups and networks throughout Ireland. Through their work 
they raise awareness of the difficulties faced by families 
in coping with substance misuse, while recognising the 
important role that families play in supporting the recovery 
of the substance-misusing family member.
Autonomous national organisation
Although founded in 2000, 2017 marked the 10-year 
anniversary of the NFSN gaining recognition as an 
autonomous national organisation. To mark this date, 
friends and stakeholders gathered in St Andrew’s Resource 
Centre on Pearse Street, Dublin, on 6 December 2017, to 
hear speakers talk about the importance of the work that 
NFSN does. Speakers included Susan Scally from the Drugs 
Policy Unit of the Department of Health; Anna Quigley from 
CityWide Drugs Crisis Campaign2; former Assistant Garda 
Commissioner Tony Hickey; researcher Philip Isard; family 
support facilitator Maureen Penrose; parent Brigid Sugrue; 
and the main speaker and founder, Sadie Grace. 
Sadie spoke with passion and emotion when she recalled 
how far the NFSN has come and its achievements of the 
last number of years. From humble beginnings, the NFSN 
was established in response to the lack of services available 
for families to where it is today, shaping national policies, 
carrying out research, advocating and lobbying for family 
rights. The NFSN’s work in highlighting the support that 
families provide received the ultimate accolade when the 
national drugs strategy formally recognised family members 
of substance misuse as ‘service users’.3 This milestone event 
is proof positive of the work being done by the NFSN.
The NFSN team: Clara Leonard 
(office manager), Conor Byrne 
(development worker), Sadie Grace 
(CEO), Ger Doherty (membership 
officer), Aoife Frances (policy 
officer), and Christy Rankin  
(training officer)
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• How to support a professional culture of quality  
in prevention
• What are the consequences of prevention polices?
• Rethinking the dynamics of primary prevention: 
mobilisation, implementation, and embeddedness in 
open systems
Speakers represented the international community working 
in the area of prevention. Posters and parallel session 
presentations covered a wide range of topics, including 
programme evaluations, methodological approaches, and 
broader debates on the role and value of prevention. 
Preventing substance use was just one of the behaviours 
addressed in the conference. Related presentations included 
an update of the International Standards on Drug Use 
Prevention from the United Nations Office on Drugs and 
Crime (UNODC),4 originally launched in 2013. These standards 
are currently being updated to take account of progress 
made in prevention research and to ensure the standards 
provide guidance based on the most up-to-date evidence 
on what makes effective prevention. The team conducting 
this work will carry out a systematic review of reviews and 
a review of primary studies to capture ‘the research on the 
emerging areas of prevention, not yet accumulated enough 
to register at the level of reviews’ (p. 30).5 
EUSPR conference: 
quality in prevention
The 8th Conference of the European Society for Prevention 
Research (EUSPR) was held in Vienna between 20 and 22 
September 2017. As reported previously in Drugnet Ireland,1 
the EUSPR was established to promote ‘the development 
of prevention science, and its application to practice so 
as to promote human health and well-being through high 
quality research, evidence based interventions, policies 
and practices’.2 The cornerstones of its work are a cross-
disciplinary network of scientists, policy-makers and 
practitioners; the development of methodologies; the 
promotion of higher education and career development in 
prevention; and the implementation of research.
The conference theme for 2017 was ‘Quality in Prevention’ 
and plenary speakers addressed a range of topics on the 
theme,3 including:
• How to attain and maintain quality in an evidence-based 
programme
• The implementation of suicide prevention in existing 
measures of addiction prevention
The event finished with a video summarising the work of 
the NFSN, including the establishment of its Drug-Related 
Intimidation Programme; its five-step method; statistics 
from the NDRDI to advocate for services; the Young Person’s 
Support Programme, and much more.
Anne Doyle
1 For further information on the National Family Support Network, 
visit http://www.fsn.ie 
2 For further information on the CityWide Drugs Crisis Campaign, 
visit https://www.citywide.ie/
3 Department of Health (2017) Reducing harm, supporting 
recovery: a health-led response to drug and alcohol use  
in Ireland 2017—2025. Dublin: Department of Health.  
http://www.drugsandalcohol.ie/27603/ 
4 For further information on the National Drug-Related Deaths 
Index (NDRDI), visit http://www.hrb.ie/health-information-in-
house-research/alcohol-drugs/ndrdi/
5 For further information on the National Advisory Committee on 
Drugs and Alcohol, visit http://www.nacda.ie/ 
6 Isard P (2016) Valuing family support: a social return on 
investment report on the value of family support for families 
coping with addiction issues. Dublin: National Family Support 
Network. Available online at http://www.socialvalueuk.org/app/
uploads/2017/02/Valuing-Family-Support-National-Family-
Support-Network-SROI-.pdf
7 For further information on the organisation Quality Matters,  
visit http://qualitymatters.ie/ 
8 SROI is an increasingly well-used and highly regarded new 
methodology that enables organisations to examine the impact 
of their work and place a financial value on it.
9 For further information on Social Value International, visit  
http://socialvalueint.org/ 
Philip Isard of Quality Matters7 outlined his research with the 
NFSN. Its collaboration was an attempt to understand the 
social and financial benefit of family support for individuals 
and the wider impact on families and organisations in Ireland. 
With a lack of research on the impact of family support, the 
study involved the Gardaí, Tusla, NFSN, Local and Regional 
Drug and Alcohol Task Forces, local addiction services, drug 
users and, of course, families themselves. Using the social 
return on investment (SROI)8 methodology, the report states 
that for every €1 invested in the NFSN, it puts back at least 
€5 into the community. As the saying goes, ‘money talks’ 
and what could be more telling than this figure. The report 
was reviewed and verified by Social Value International9 and 
provides evidence of what families already knew but which is 
now confirmed.
Personal testimonies
To remind the audience of the realities for families living 
with substance misuse, Brigid Sugrue, a mother directly 
impacted by drugs misuse and ultimately death, told her 
story. In an often emotional speech, Brigid spoke of the 
‘lifeline’ that was the Bereavement Support Programme 
of the NFSN and reiterated the importance of the work 
of NFSN. Also ‘on stage’ was Maureen Penrose, who 
spoke eloquently about the first of many services of 
commemoration: ‘We’re suffering, we’re many, we have a 
voice.’ She spoke of how you ‘won’t cry alone in the NFSN’ 
and that ‘you’re always supported’.
NFSN — 10 years continued
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Conference on drug 
use in families and 
communities
On 22 November 2017, a community conference ‘Drug  
use in families and communities: reducing harm, supporting 
recovery’ took place as part of Bray Drugs Awareness Month. 
The event was coordinated by the Bray Drugs Awareness 
Forum (BDAF). BDAF was established in 1992 and comprises 
representatives from community, voluntary and statutory 
organisations, all with a shared interest in drugs issues.  
The forum works to provide education, awareness, 
prevention, training, and information on drugs issues for  
the Bray community. 
Approximately 100 people attended the conference, 
including members of the forum and other stakeholders 
working in the sector in the Bray area, as well as members 
of the wider community. The programme included a 
presentation from Anna Quigley of CityWide Drugs 
Crisis Campaign on the new national drugs strategy. She 
presented an overview of the strategy and identified some 
key challenges to its delivery: challenges to sustaining an 
interagency partnership approach; those related to local 
community involvement, including the impact of cuts on 
local drugs services and general community services; and, 
features of the overall environment in which the strategy 
is to be delivered, for example, the lobbying power of the 
alcohol industry and the increasing complexity of drugs and 
their markets.
Professor Catherine Comiskey and Karen Gilligan of Trinity 
College Dublin presented on research they carried out 
to develop a family and community informed local drugs 
strategy for children of parents who use drugs. Clara Geaney 
of Ballyfermot Local Drugs and Alcohol Task Force presented 
the findings of her research on women, alcohol, health, and 
treatment. The goals of the study were to support screening 
assessment and treatment for women experiencing 
problematic alcohol use within primary care settings; and 
to strengthen referral between primary care services and 
specialised substance misuse services.
Presentations were also made by Adrian McKenna of 
Crosscare Homeless Services and Maureen Penrose, a drug 
worker who previously worked with Mountview/Blakestown 
Community Drugs Team. Adrian spoke of the increasing 
demand on their services and the diverse needs of their 
users. He also highlighted the need for people to be given 
permanent rather than temporary accommodation. Maureen 
spoke of her experiences of supporting families of drug 
users. She also presented her spoken word piece entitled 
‘Grandmothers’.1
Further information on the conference can be obtained 
from Dr Clay Darcy, drugs education and prevention 
development officer who works on behalf of the BDAF, at 
braydrugsawarenessforum@gmail.com.
Lucy Dillon
1 The video of Maureen Penrose can be viewed at http://www.
drugs.ie/multimedia/video/grandmothers_by_maureen_penrose 
Irish papers presented at the conference included:  
• ‘Because we do it together’ family based prevention: 
a ten-year overview of implementation and outcomes 
of the Strengthening Families Programme in Ireland’, 
presented by Donna Butler of the Families Matter 
Programme. 
• ‘Factors concerning access to a potential drug 
consumption room’, presented by Emma Atkin-
Brenninkmeyer of Trinity College Dublin. 
• ‘Getting prevention on the political agenda: the  
Irish experience of influencing policy and practice’, 
presented by Marian Quinn of the Prevention and Early 
Intervention Network.
• ‘Alcohol drinking behaviours and perceived norms: 
longitudinal trends among Irish adolescents aged 12—15 
years’, presented by Kathy-Ann Fox of the National 
University of Ireland, Galway.
Lucy Dillon
1 Dillon L (2017) EUSPR conference: sustainable prevention 
in a changing world. Drugnet Ireland, 61: 21. http://www.
drugsandalcohol.ie/27212/ 
2 More information on the EUSPR and the conference is available 
at www.euspr.org.
3 Plenary speakers’ presentations are available to download at 
http://euspr.org/plenary-talks/
4 United Nations Office on Drugs and Crime (UNODC) (2015) 
International standards on drug use prevention. Vienna: 
UNODC. http://www.drugsandalcohol.ie/19481 
5 European Society for Prevention Research (2017) Quality in 
prevention: 8th EUSPR Conference and Members’ Meeting; 
Vienna, 20th—22nd September 2017. Warsaw: EUSPR.  
http://www.drugsandalcohol.ie/27987/ 
EUSPR conference continued
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18 Fifty-seven per cent of the current users had considered 
changing their cannabis use in the past three months. 
In response to an open-ended question about what 
their reasons would be for reducing their use, financial 
implications emerged as the most important factor (20%). 
Others were employment (17.5%), physical health (17.5%), 
family relations (15%), and appearance, children, and mental 
health (all at 5%). 
Cutting across the study was the finding that when compared 
to the street group, the young people who were in education 
or training and used cannabis used it less frequently; used a 
smaller amount when used; spent less on it; and were more 
motivated to change their use.
Recommendations
The final chapter of the report makes a number of 
recommendations for interventions and responses to the use 
of cannabis among young people.
Current knowledge base: There is a lack of knowledge about 
the current strains of herbal cannabis among some members 
of the community, service providers, and other stakeholders. 
The authors suggest that the ‘high level of apathy’ (p. 30) 
towards cannabis is often based on people’s experiences 
of former strains of the drug that were of a lower potency. 
They recommend that stakeholders ensure that their 
institutional knowledge on problematic cannabis use is in 
line with current evidence. Also, that priority should be given 
to raising awareness among users, family members, and 
concerned others about the new strains of cannabis. 
Prevention and early intervention: There needs to be ongoing 
support for prevention and early intervention responses to 
cannabis use. The authors suggest challenging the norms and 
attitudes to cannabis use, and increasing local and service 
user knowledge about cannabis and the impact of its use.
Targeted responses to daily users: Given the findings that a 
significant proportion of daily users of cannabis expressed 
an interest in changing their behaviour, the authors highlight 
the need to have tailored services to meet their needs. It is 
suggested that services draw on the international evidence 
base for this purpose.
Maintaining the focus of cannabis on community 
conversations and responses: The authors reflect on the 
‘heightened interest’ (p. 31) that cannabis use has attracted 
as a result of the increasing prevalence of its problematic 
use, and its negative impact on users and communities, 
including problems related to drug-related debt and 
intimidation. They note that the momentum gathered 
through this and the consultation process for the new 
national drugs strategy should be maintained. Cannabis-
related responses should be considered at all levels of policy 
and on national strategic platforms. 
Lucy Dillon
1 O’Brien K and Foley B (2017) ‘It’s only weed’: rethinking our 
response to young people’s cannabis use. Dublin: Ballymun 
Youth Action Project. http://www.drugsandalcohol.ie/27246/ 
2 The Equal Youth Cannabis Initiative in Ballymun is made up of 
representatives from a number of service providers working in 
Ballymun with early school-leavers (aged 16—24 years). They 
work to a model of interagency cooperation to meet the needs 
of these young people.
Rethinking  
the response to 
cannabis use
The study ‘It’s only weed’: rethinking our response to young 
people’s cannabis use in Ballymun was carried out by 
Ballymun Youth Action Project, and published in May 2017.1 
Service providers based in Ballymun, Dublin who work with 
early school-leavers (aged 16—24 years)2 noticed that a 
cohort of young people were becoming increasingly difficult 
to motivate both to turn up for appointments and to engage 
with when attending key working sessions. It was decided 
to explore the factors that were impacting on retention and 
progression rates for this group. Through discussions among 
key stakeholders, cannabis use was identified as contributing 
to the problem; programme participants were reporting both 
‘high levels of use and, for some, high levels of drug debt’ (p. 
6). The research had two aims:
• To provide a rapid assessment of cannabis use 
prevalence within particular education/training centres 
and community settings in Ballymun
• To explore the relationship that the young people in 
these settings have with cannabis
Data were collected from young people attending two youth 
education/training projects and one ‘street’ site, i.e. young 
people not engaged in any education and training programme. 
A questionnaire was developed based on the ‘existing evidence 
based tool’, i.e. the cannabis use problem identification tool 
(CUPIT) (p. 12). Overall, 73 young people from the training 
projects took part and 23 from the street site. 
Key findings
Seventy-eight per cent of young people had used cannabis in 
their lifetime. Of the 58 who had used in the last 12 months, 
35 (60%) were using daily. In response to the question ‘How 
does cannabis fit into your life?’, among the most popular 
responses were that using cannabis ‘is relaxing’ (22%), ‘helps 
with boredom’ (18%), ‘helps me sleep’ (15.5%), ‘helps me 
forget problems’ (11%), and makes me ‘feel less nervous 
and stressed’ (10%). The authors suggest that cannabis has 
become increasingly culturally tolerated and accepted in 
their community as a way of coping with problems. This 
can result in a more minimised view of cannabis and its 
negative impacts on the user and those around them. They 
argue that similar cultural accommodation has existed in 
their community and other similarly marginalised ones for 
benzodiazepines and other prescribed medications. 
Based on their research and an examination of the literature 
on cannabis use, the authors identify ‘significant concerns’ 
(p. 26) with the impact of cannabis use on young people’s 
engagement with education and the long-term impact on their 
memory and brain function. Daily cannabis users in the study 
were found to be experiencing problems with health, finances, 
family relationships, and educational/vocational performance. 
Some described an ‘inability to regulate and control their use’ 
(p. 27) and this was associated with a lack of engagement in 
structures such as educational or vocational training.
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Innovation and growth 
• Apply appropriate growth strategies to existing  
service level agreement objectives.
• Develop recovery-focused integrated care  
pathways to better meet the needs of participants  
with dual diagnosis.
• Continue to increase knowledge of evidence-based 
practice in addressing drug and alcohol use and  
mental health.
• Maintain a keen focus on the health and wellbeing of  
our participants, staff and wider community.
Collaboration and communication
• Influence attitudes and behaviours locally to reduce 
stigmatisation and marginalisation of people with 
addiction and mental health problems.
• Promote and raise awareness about the work of FAST 
within the community.
Lucy Dillon 
1  More information is available on the organisation’s website at  
http://www.fastltd.ie 
New strategy for 
Finglas Addiction 
Support Team
On 20 October 2017, the Finglas Addiction Support Team 
(FAST) launched their new strategic plan for 2017—2020 
entitled ‘Delivering our ambition: recovery for a better life’.1 
FAST offers a range of services, including drop-in; addiction 
counselling; polydrug use service; aftercare; family support; 
and the Recovery Coach programme. Their vision is ‘leading 
an innovative centre of excellence where people can recover 
and have fulfilled lives in their community’; and their mission: 
‘we will provide accessible quality services for those affected 
by drug and alcohol use and mental health issues’. These are 
supported by four values: dignity, integrity, empowerment, 
and quality.
The new strategy has three priority areas, each of which is 
underpinned by a set of objectives: 
Sustainability
• Ensure that resources are in place to underpin current 
and future services.
• Ensure that best practice governance is maintained and 
monitored throughout the organisation.
• Ensure that FAST has a supportive culture, robust 
organisational structure, and suitable competencies.
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18 • A lack of targeted and culturally appropriate services
• A lack of knowledge of services among potential  
service users
• Language difficulties and, where a translator is used, 
concerns about confidentiality
• Community shame – the shaming of a person or group 
within their own community, as well as the risk that a 
person or group would shame that whole community
• Perceived and experienced racism, discriminatory 
behaviour and stereotyping among service providers
• Concerns about a person’s legal or immigration status, 
where this is precarious. This includes concerns that 
a person would be deported or experience other 
repercussions if they approach services. This was 
particularly problematic for asylum seekers and 
undocumented migrants.
Second generation
A recurring theme throughout the report was the particular 
set of challenges faced by second-generation migrants 
that put them at increased risk of problematic drug use 
— an issue that has been recognised internationally. The 
reasons for this included ‘their specific circumstances in the 
integration process’ (p. 12) and their having ‘specific stresses 
in grappling with new and old identities’ (p. 13). Furthermore, 
dealing with racism and seeking peer acceptance within a 
culture that is different from that of their parents presents 
challenges. The hierarchical structures that exist within 
these communities and that influence and protect the young 
people can break down over time, providing an environment 
in which drug use may become a problem. There are also 
particular challenges to delivering prevention within this 
context. For example, parents feeling ill-equipped to discuss 
drugs with their children. 
Informing policy-makers
The report identifies a number of ways in which policy-
makers could be better informed about the issues facing  
new communities and other BME groups. These include:
• To document the stories of people from these groups 
who are involved in problematic drug use. These could  
be used to identify the range of issues faced in  
accessing services.
• To encourage the wider use of an ethnic identifier by 
service users, which would make BME people more visible 
to policy-makers
• To provide training for cultural competence among 
policy-makers
• To support research on the topic of drug use among  
BME groups
• To support processes of ‘mutual education’ between 
drug service providers and organisations working with 
BME communities
• To encourage community-based service providers to 
report on the diversity of their service users within  
policy fora
• To improve representation of key stakeholders from 
within BME groups in policy deliberations
• To encourage the inclusion of BME organisations with the 
Task Forces
Problematic drug use 
and the needs of new 
communities and 
BME groups
The report Stimulating and supporting a Black and minority 
ethnic voice on drug issues1 was published in April 2017 
by CityWide Drugs Crisis Campaign, the national network 
of community activities and organisations involved in 
responding to drug-related issues. The research aimed ‘to 
explore possible structures and processes through which 
to engage with, hear the voice of, and empower Black and 
minority ethnic communities in relation to issues of drug use’ 
(p. 5). It was carried out by Niall Crowley, an independent 
public policy researcher with particular expertise in human 
rights and equality. 
The findings of the report are based on 14 interviews with 
those working in community-based drug service provision 
(n=9), and representatives of Black and minority ethnic (BME) 
organisations (n=5). The author also reviewed two pieces of 
earlier research that explored the issue of drug use among 
new communities in Ireland.2,3 
Addressing the varying needs of new migrant communities 
as well as those of BME groups more generally is complex. 
The report focuses on the needs of new communities and 
their experience of cultural difference, in particular how this 
may impact on their experiences of accessing services and 
influencing policy in the area of drug use. Chapter 4 of the 
report focuses on ‘difference’, which is explored under the 
headings of situation, experience, and identity. The author 
emphasises that: 
[It] underpins the need for a specific focus on these 
communities in policy and a specific place at the 
table in deliberating on policy. Difference points to 
specific risk factors, patterns of drug use, service 
needs, and communication channels that must be 
accommodated in policy and provision. (p. 15)
A hidden problem
There was general consensus among those interviewed 
that problematic drug use is an issue among BME groups, 
including new communities. However, its extent is unknown 
and its usage perceived to be largely hidden. While the 
National Drug Treatment Reporting System (NDTRS) of the 
Health Research Board has used an ethnic identifier for 
BME groups since 2008, the report suggests that a lack of 
presentation to appropriate services means that this is not 
yet a reliable indicator of the true extent of the problem. The 
report calls for more research so that this assessment can 
be substantiated. 
Barriers to accessing services
Barriers to accessing services for new communities and BME 
groups are identified, including:
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• Considering the need for specialist referral pathways for 
specific groups who may not otherwise attend traditional 
addiction services (i.e. those who engage in chemsex).
• Providing antiracism, cultural competency, and equality 
training to service providers.
• Ensuring all services engage in ethnic equality monitoring 
by reporting on the nationality, ethnicity and cultural 
background of service users for the NDTRS and treat 
related disclosures with sensitivity.
The Health Service Executive is identified as the lead agency 
in this work, with the community and voluntary sector as 
partners. The scope of these actions is similar to those 
of the previous strategy; and there continues to be no 
reference to participation by organisations representing new 
communities in the policy structures of the new strategy. 
Following on from the report, CityWide held a round-table 
event with representatives from community drug service 
providers, BME organisations, and task forces. The aims of the 
session were to build cultural competence and knowledge 
among service providers about the situation, experience and 
identity of these communities, as well as to develop capacity 
and commitment among BME organisations to take up issues 
of problematic drug use in their policy work.5
Lucy Dillon
1 Crowley N (2017) Stimulating and supporting a Black and 
minority ethnic voice on drugs issues. Dublin: CityWide Drugs 
Crisis Campaign. http://www.drugsandalcohol.ie/27501/
2 Corr C (2004) Drug use among new communities in  
Ireland: an exploratory study. Dublin: National Advisory 
Committee on Drugs / Merchants Quay Ireland.  
http://www.drugsandalcohol.ie/5897/
3 Kelly C, Fitzpatrick C and Nic Gabhainn S (2009) Substance use 
in new communities: a way forward. Galway: Western Region 
Drugs Task Force. http://www.drugsandalcohol.ie/11508/
4 Department of Health (2017) Reducing harm, supporting 
recovery: a health-led response to drug and alcohol use in 
Ireland 2017—2025. Dublin: Department of Health.  
http://www.drugsandalcohol.ie/27603/
5 Personal communication with CityWide.
New communities and national drug policy
One of CityWide’s aims in commissioning this report was  
‘to enable Black and minority ethnic communities to 
influence the development and implementation of the 
National Drugs Strategy’ (p. 5). The author notes that by  
the end of the timeframe of the previous drug strategy 
(2009—2016), there was ‘little evidence reported of action  
in relation to new communities on foot of these 
commitments’ (p. 7), i.e. commitments both to address  
the treatment and rehabilitation needs of new communities; 
and to develop engagement with new communities as a 
group identified as ‘at risk’ in relation to drug use. In the 
report, Crowley concludes: 
Policy and provision in relation to problematic 
drug use have yet to respond appropriately and 
adequately to the needs of Black and minority 
ethnic communities. Institutional structures to 
underpin this policy and provision have yet to 
adequately engage the voice of these communities. 
This has happened in a context where, after a 
promising start, policy and provision on integration 
of new communities over the past decade has been 
limited. (p. 27)
The new national drugs strategy (2017—2025) was launched 
in July 2017.4 The needs of migrant communities were 
raised in the public consultation for the new strategy’s 
development. It is recognised in the strategy that migrant 
communities ‘may also experience barriers to accessing 
services or maintaining treatment, for a variety of reasons’ 
(p. 47).4 One of the actions from the strategy’s action plan 
(2017—2020) sets out to improve the capacity of services 
to accommodate the needs of people who use drugs 
and alcohol from specific communities (including new 
communities). This can be achieved by:
• Fostering engagement with representatives of these 
communities, and/or services working with them, as 
appropriate.
Needs of new communities continued
Community service: 
an alternative to 
imprisonment in 
Ireland
In October 2017, the Irish Penal Reform Trust (IPRT) in 
association with the Irish Criminal Bar Association held a 
seminar and launched a PhD research project ‘Examining the 
comparative use, experience, and outcomes of community 
service orders as alternatives to short prison sentences in 
Ireland’ by Dr Kate O’Hara.1
Background
Community service orders (CSOs) first emerged in Ireland 
following the enactment of the Criminal Justice (Community 
Service) Act 1983 in December 1984.2 According to this 
legislation, a CSO could only be enforced after imprisonment 
had been considered. With the aim of overcoming issues 
of underutilisation, reducing short-term prison (STP) stays, 
and helping offenders and the wider society, the Act was 
amended in 2011 to allow and encourage courts to impose a 
CSO as an alternative to short-term sentences (<12 months) 
as long as certain criteria were met.3
Aims and objectives
The main objective of the O’Hara study was twofold: first, to 
examine how CSOs were utilised and, second, to compare 
views, experiences and recidivism rates between two groups: 
those that received CSOs (n=6784) and those that received 
STP sentences (n=5231).
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Mary Rogan, Mr David Perry BL, and the IPRT welcomed the 
findings of the study and acknowledged that it increased 
the knowledge and understanding of CSOs in Ireland. The 
Probation Service provided an outline of changes made thus 
far and examples of work carried out by offenders that have 
received CSOs to date and their plans for the future. 
To coincide with the seminar, the IPRT published a discussion 
paper where they explore how the application of CSOs 
within the Irish criminal justice system can be improved.4 
They identify a number of areas that need to be addressed 
to achieve this, such as evidence-informed policy, legislative 
reform, monitoring and review, promoting consistency, 
raising awareness, tailored community sanctions, addressing 
substance misuse, and further research. 
Professor Rogan drew attention to the fact that the data 
in this study came from a variety of sources and of the 
importance of researchers having access to accurate 
and good quality data. She believes that this will provide 
a sustainable model to enable further exploration of 
the impact and usefulness of policies that are being 
implemented within the Irish justice system, while also 
allowing for changes and improvements to be captured. 
Collaborative work between the academic sector and 
practice and policy-makers was identified as the best route 
to achieving this. 
Ciara H Guiney 
1 O’Hara K (2016) Examining the comparative use,  
experience, and outcomes of community service orders  
as alternatives to short prison sentences in Ireland.  
Dublin: Dublin Institute of Technology.  
http://www.drugsandalcohol.ie/27991/ 
2 Criminal Justice (Community Service) Act 1983 at  
http://www.irishstatutebook.ie/eli/1983/act/23/enacted/ 
en/print
3 Criminal Justice (Community Service) (Amendment) Act 2011  
at http://www.irishstatutebook.ie/eli/2011/act/24/enacted/ 
en/html
4 Irish Penal Reform Trust (2017) Community service in Ireland: 
a qualitative exploration of one alternative to short-term 
imprisonment. Dublin: Irish Penal Reform Trust.  
http://www.drugsandalcohol.ie/28310/
Methodology
The study used a mixed methodology approach. Data 
related to STPs (n=6784) and CSOs (n=5231) for the years 
2011 and 2012 were provided by the Irish Prison Service 
and the Probation Service. This was subsequently linked to 
criminal history and rearrest data from An Garda Síochána. 
The analysis involved a comparative analysis (quantitative) 
and interviews (qualitative, n=21). Lastly, the frequency of 
rearrests was examined 12 and 24 months after leaving prison 
or beginning the CSO.
Results
The results indicated that, although offenders in the STP 
group were older than those in the CSO group, the number 
of previous convictions for the STP and CSO groups was 
similar. The likelihood of obtaining a CSO was influenced 
by province, court location, and court type. More CSOs 
were issued in Ulster, while fewer were issued in Munster 
and Connacht. No association was shown between CSOs 
and Leinster. The analysis of courts by location indicated 
that more CSOs were issued from rural courts. Moreover, a 
higher number of offenders received a CSO when a court 
was located far from a prison. These results should be 
interpreted with caution however as many of the effect sizes 
were small.Sanctions for drug offences resulted in a higher 
number of CSOs than STP sentences. Although this outcome 
was significant, the effect size was low. The average CSO 
length for drug offences was 164 hours (SD=56.1), while the 
average alternative prison sentence was 6.7 months. 
For individuals whose original offences were drug offences:
• At six months, rearrests were higher in the CSO group 
when compared to the STP group, 21% (n=121) and 17% 
(n=68), respectively. 
• At one year, rearrests were higher in the CSO group 
when compared to the STP group, 33% (n=194) and 30% 
(n=120), respectively.
• At two years (2011 only), rearrests were lower in the CSO 
group when compared to the STP group, 50% (n=151) and 
54% (n=116), respectively.
Only a small proportion of offenders whose original 
conviction was for drug offences were reconvicted for drug 
offences; 21% (n=25) received CSOs and 13% (n=18) received 
STPs. Subsequent convictions included violent offences, 
property offences, road traffic offences, public order 
offences and other offences. Information on other offence 
categories can be viewed in the thesis.1
Conclusion
O’Hara concluded that this was the first study of its kind to 
be carried out in an Irish jurisdiction. In order to implement 
and consider CSOs and other alternatives to imprisonment as 
acceptable, more research was needed along with changes 
to policy and practice.
Community service continued
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Community engagement and public safety 
One of the core strengths of AGS is its ability to engage 
with and be part of the community. This plan builds on this 
strength via collaborative work that stresses the importance 
of crime prevention initiatives. In order to overcome the 
debilitating effects of fear caused by criminality, the aim is 
that AGS will have a highly visible presence and will continue 
to develop strong relationships within communities to 
increase trust and confidence. These steps will be further 
enhanced by the use of evidence-based interventions. 
Organisational development and capacity 
improvement
In 2016, the Modernisation and Renewal Programme 
2016—2021, a five-year initiative that aims to update the 
culture and structure of AGS, was launched.3 The initiative 
outlines the mission, direction, plans and challenges for 
AGS from 2016 to 2021. The programme is expected to 
give rise to a service that is more modern, accountable, 
professional, and performance driven. As an organisation, 
AGS recognises that an essential ingredient necessary 
to achieve this outcome is the unrelenting perseverance 
and steadfastness from the Garda, civilian and reserve 
members it employs. They are committed to making the 
right tools, guidance and support, appropriate training and 
development available along with the right leadership so 
that employees can carry out their roles effectively. They 
believe that this will enable AGS to take its place among 
world-class policing and security services globally. It is 
expected that the 2017 Policing Plan will have a genuine 
impact on the communities that AGS serves.
Ciara H Guiney
1 An Garda Síochána (2017) An Garda Síochána Annual Policing 
Plan 2017. Dublin: An Garda Síochána.  
http://www.drugsandalcohol.ie/27736/
2 An Garda Síochána (2016) An Garda Síochána statement 
strategy July 2016—2018. Dublin: An Garda Síochána.  
http://www.drugsandalcohol.ie/27305/ 
3 An Garda Síochána (2015) An Garda Síochána modernisation 
and renewal programme 2016—2021. Dublin: An Garda 
Síochána. http://www.drugsandalcohol.ie/27306/ 
An Garda Síochána 
Policing Plan 2017
An Garda Síochána Annual Policing Plan 2017 identifies the 
main policing concerns for 2017.1 Consistent with previous 
plans, it has considered the views of the community; An 
Garda Síochána (AGS); external stakeholders, including 
the Minister for Justice and Equality as well as the Garda 
Síochána Strategy Statement July 2016—2018;2 ministerial 
directives; resource capacity; Joint Policing Committees; 
crime data analysis; and research. However, for the first time, 
in contrast to previous policing plans, priorities and targets 
have been agreed in talks between AGS and the Policing 
Authority, who will monitor how AGS will meet those targets. 
A number of areas have been highlighted by AGS in 2017: 
national and international security; confronting crime; roads 
policing; community engagement and public safety; and 
organisational development and capacity improvement.
National and international security
Due to ongoing challenges arising from terrorism and how it 
is funded, counterterrorism tactics are being strengthened. 
Drawing on an interagency approach between AGS, 
community and partner groups, and other law enforcement 
agencies both nationally and internationally, the emphasis 
is on prevention, overcoming challenges, sharing Intel, 
and prosecution. A key component of major emergency 
preparation involves training and risk assessment.
Confronting crime
A key element of AGS strategies is to deter crime. Existing 
multiagency approaches north and south of the Irish border 
have been effective in the fight against cross-border crime. 
This has been further strengthened by the formation of the 
Drugs and Organised Crime Bureau, which aims to actively 
target individuals associated with organised crime.
Roads policing
Saving lives is important to AGS. One area that influences 
this outcome is road safety. Already via multiagency 
collaboration there has been a decrease in road deaths. 
However, this plan acknowledges that more needs to be 
done to ensure road safety in Ireland is similar to that in 
other leading European countries. In order to do this, AGS 
aims to implement relevant legislation; analyse collisions; 
carry out ‘targeted intelligence-led operations’; and increase 
the use of automatic number plate recognition technology 
(p. 12). Moreover, the Garda Traffic Corps is to be renamed 
the Garda Roads Policing Unit; this change will also involve 
greater visibility and policing functionality on Irish roads.
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Property crime, such as burglary and theft, are widespread in 
Ireland. However, the extent of crime and later victimisation 
is not. Moreover, what may be common in one area may not 
occur at all in another area. Hence, specific crimes are to 
be addressed in local policing plans and targeted by crime 
coordination units in each Garda region. As new crimes 
emerge, for example cybercrime, appropriate strategies 
centred on best evidence-based practice will be circulated 
to relevant stakeholders.
Monitoring, review and governance
The strategy will be monitored and reviewed to make certain 
that it continues to be aligned with the principles of the five-
year TRUST programme.3 The strategy is being supervised by 
Superintendent, Garda Crime Prevention National Centre of 
Excellence in consultation with Regional Risk Compliance and 
Continuous Improvement Superintendents (p. 8). Within 18 
months of commencement, an evaluation will be carried out, 
where any improvements identified will be acted upon.
Implementation plan
The implementation plan outlined by AGS centres on four 
pillars: building capacity, community partnership and 
collaboration, customised approaches, and crime prevention 
messages. AGS has identified the key objectives, actions 
to be taken, who is responsible for each action, and the 
expected outcomes (more detail available in Section 9 of the 
strategy document).1
Conclusion
Having a crime prevention strategy is undoubtedly the 
most apt approach to address criminality and ensure safety 
within the community. The research suggests that the most 
effective way to reduce crime is to avail of a wide range 
of interventions. Moreover, Gardaí cannot singlehandedly 
resolve criminality in Ireland; this can only be achieved 
by engaging all of Irish society, from state agencies right 
down to individuals living in the community. This Garda-
driven strategy is welcomed and will take important steps in 
preventing and reducing crime in Ireland. 
Ciara H Guiney 
1 An Garda Síochána (2017) Crime prevention and reduction 
strategy: putting prevention first. Dublin: An Garda Síochána. 
http://www.drugsandalcohol.ie/27147/ 
2 Taking care of our communities; Renewing our culture;  
Unified governance and leadership; Supporting our people;  
Technology-enabled.
3 An Garda Síochána (2015) An Garda Síochána modernisation 
and renewal programme 2016—2021. Dublin: An Garda Síochána. 
http://www.drugsandalcohol.ie/27306/ 
Crime prevention 
and reduction 
strategy: putting 
prevention first
In April 2017, An Garda Síochána (AGS) published a crime 
prevention and reduction strategy.1 This is not a national 
strategy but a ‘proactive garda strategy’ (p. 3) that aims to 
address criminality in Irish society. It provides a structure 
that endeavours to target specific criminal activities at a 
local, regional, or national level.
Purpose and expected outcomes
The central premise behind the strategy is that it would 
act as a resource and provide guidance on appropriate 
procedures that prevent and reduce crime. It will take 
a ‘whole organisational approach’ (p. 9) within AGS but 
will also consider the wider role of AGS where it acts as a 
coordinator and collaborator with partner agencies and 
other agencies in Ireland to reduce crime. It is presumed 
that a number of outcomes will be realised. For example, it 
is expected that the capability within AGS to prevent crime 
will increase. It is anticipated that crime and reoffending 
will reduce. Moreover, heightened safety and security within 
neighbourhoods should lead to a drop in the fear of crime, 
and the risk of becoming a victim of crime. 
Principles of good practice
The strategy is informed by best international practice and 
UN Guidelines for the Prevention of Crime. AGS initially 
evaluated existing strategies and drew on what was learned 
from them to identify the most appropriate approaches to 
be used in Ireland. Although the themes that emerged were 
in alignment with the TRUST2 transformation programme 
— which is currently reforming and modernising the 
AGS3 — such as collaboration with agencies from local to 
international level, programme integration across agencies, 
drawing on research and scientific evidence, measureable 
results, suitable analysis and funding, it was concluded that 
no intervention in isolation could reduce crime. What was 
considered vital was a multifaceted, multiagency approach 
centred on problem-solving but also based on strong 
scientific evidence. 
Effective crime prevention strategies
It is highlighted that the Crime prevention and reduction 
strategy document is a working document and hence would 
need continuous appraisal, analysis, re-evaluation, and revision 
when necessary. It is acknowledged that what succeeds in 
one setting may not be suitable for another. Therefore, having 
a strategy that is sufficiently robust to achieve its outcomes is 
crucial, but at the same time it is essential that it is amenable 
to change or fine-tuning when needed.
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are also submitted by the Garda Síochána Ombudsman 
Commission (GSOC), Customs and Excise, and Military 
Police. A set procedure is in place to accept cases; following 
acceptance of substances by FSI reception or case intake 
staff, items are stored safely and securely and then passed 
to a relevant scientist for analysis. At all times the chain of 
custody is closely monitored.
Figure 1 provides a summary of drug trends between 2004 
and 2016 for drugs that were submitted to FSI for analysis. 
Following a peak in overall drug submissions in 2009, 
submissions declined until 2012. Between 2012 and 2014 a 
slight increase was evident. Since 2014, a slight decreasing 
trajectory has been shown. A further analysis for drugs that 
contravene Sections 15 and 17 of the Misuse of Drugs Acts 
illustrated that between 2008 and 2016 the changes year on 
year have been very small.
Figure 2 provides a summary of the number of cases 
analysed by drug type that contravened Section 3 of 
the Misuse of Drugs Acts in 2016. The majority of cases 
submitted were for cannabis (44%), followed by powder, and 
then heroin, 24% and 20.7%, respectively. 
Forensic Science 
Ireland: annual 
report 2016
Forensic Science Ireland (FSI), originally known as the 
Forensic Science Laboratory, delivers a scientific service 
that supports the Irish criminal justice system by analysing 
samples that are gathered at crime scenes (e.g. DNA, 
chemistry, and drugs). Moreover, it presents expert evidence 
in court, provides training, and carries out research. In order 
to do this effectively, scientists and analysts within the FSI 
draw on best international standards. In May 2017, the FSI 
published their annual report, which provided an overview of 
work carried out in relation to drugs in the course of 2016.1 
The majority of cases received by FSI centre on substances 
that violate the Misuse of Drugs Acts 1977—2015. Generally, 
substances are seized by An Garda Síochána; however, they 
Figure 1: Trends in drug submissions to FSI from 2004 to 2016 
Source: Forensic Science Ireland annual report 2016, Figure 3, p. 13
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Figure 2: Different types of Section 3 analysis carried out by 
the FSI Drugs Section. Section 3 offences involve possession of 
illegal drugs for personal use
 
Source: Forensic Science Ireland annual report 2016, Figure 4, p. 14
Figure 3: Different types of Section 15 analysis carried out by the 
FSI Drugs Section (Section 17 is also shown). Section 15 refers to 
possession of illegal drugs for sale or supply offences; Section 17 
refers to cultivation or growth of illegal drugs
Source: Forensic Science Ireland annual report 2016, Figure 5, p. 14
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18 to a case that occurred at a house party attended by 
young people in Cork in 2016. Powder that was assumed 
to be a designer drug called 2CB was consumed and high 
levels taken as a result. FSI later identified the powder as 
24I-NBOMe (N-Bomb), a toxic hallucinogenic drug. In this 
instance, the amount consumed was one hundred times 
higher than the normal dose and resulted in the death of one 
young male.
Court appearances
In 2016, requests for FSI to appear in court were low. Despite 
this, defence teams visited FSI on a number of occasions, 
many of which were connected to the reassessment of drug 
seizures (n=34). 
Purity
Purity levels in cocaine were generally 40%. A number of 
other compounds were found, such as levamisole (used 
by vets), benzocaine and lignocaine (used by dentists) and 
phenacetin (used as an illegal painkiller). With regard to 
heroin, purity levels were about 33%, and other compounds 
present included combinations of phenacetin, paracetamol, 
and caffeine.
Out-of-hours service
An out-of-hours service consisting of one scientist and a 
small team (n=20) were at hand to attend crime scenes and 
carry out laboratory work when needed. Overall, urgent drug 
analysis was required seven times and crime scene visits 
occurred 14 times, one of which was to a clandestine drug 
laboratory.
Ciara H Guiney
1 Forensic Science Ireland (2017) Forensic Science Ireland annual 
report 2016. Dublin: Forensic Science Ireland.  
http://www.drugsandalcohol.ie/27308/ 
 
Similarly, under Section 15, the prevailing drug submitted 
was cannabis (32%), followed by powder and heroin, 27% 
and 22%, respectively, while under Section 17, cannabis 
cultivation accounted for 6.5% of the analysis performed 
(see Figure 3).
New substances
A number of new drugs were identified in Ireland in 2016, 
including:
• Benzodiazepine drugs: phenazepam, nitrazolam, 
etizolam, chlorodiazepam
• Cathinone (stimulant) drugs: pentylone, dipentylone, 
dibutylone, ethylhexedrone, N-ethylpentedrone, α-PVP, 
clephedrone, MPHP, PV8 (α-PHP), PV9 (α-POP), chloro-
PVP, 4-chloro-α-PPP
• Synthetic cannabinoids: 5F-MDMB-PINACA, 5F-AKB-48, 
5F-PB-22
• Tryptamines (stimulant) drugs: methyltryptamine, 
dimethyltryptamine, 5-MeO MiPT
• NBOMes: 25I-NBOMe
• Fentanyl (opiate-type) drugs: fentanyl, pentanoyl 
fentanyl, 2-flourofentanyl
• Other drugs: 3-flourophenmetrazine  
(stimulant-type drug) 
The emergence of new substances creates a challenge for 
FSI, as no reference standards are available to which they 
can be compared. Moreover, individuals that use these new 
products are at higher risk, as toxicity levels are substantially 
higher than similar drugs. For example, the report refers 
FSI annual report continued
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UPDATES
Recent publications
The following abstracts are cited from published journal articles 
recently added to the repository of the HRB National Drugs 
Library at www.drugsandalcohol.ie 
POLICY AND LEGISLATION
Ireland’s Public Health Bill: crucial to reduce alcohol harm
Murray F (2017) Lancet, 390 (10109): 2222.  
http://www.drugsandalcohol.ie/28100/ 
Ireland has become the fourth heaviest drinking nation in the 
Organisation for Economic Co-operation and Development 
in terms of quantity of alcohol consumed, and ranked joint 
third for binge drinking in an analysis of 194 nations by WHO. 
Irish adults consume on average 11·5 L of pure alcohol per 
person every year, an increase of more than 100% compared 
with 60 years ago. Most alcohol in Ireland is now consumed 
at home and alcohol retailing off licences have increased by 
five-fold since 1990. Despite high alcohol taxes and duties, 
cheap alcohol is sold in many more outlets.
PREVALENCE AND CURRENT SITUATION
A national survey of online gambling behaviours
Columb D and O’Gara C (2017) Irish Journal of  
Psychological Medicine. Early online.  
http://www.drugsandalcohol.ie/28197/ 
The aim of this study is to look at an Irish population 
in relation to the online gambling activities people are 
engaging with, the reasons for gambling online, their 
attitudes to online gambling and the financial/mental health 
consequences of online gambling.
Online gamblers in Ireland share similar behavioural profiles 
to online gamblers in the United Kingdom and worldwide. The 
majority of participants in this research have been adversely 
affected from both a mental and financial perspective due to 
their gambling behaviours.
A high prevalence rate of a positive screen for cognitive 
impairment in patients with Human Immunodeficiency Virus 
attending an Irish clinic
McNamara PH, Coen R, Redmond, J, Doherty CP and Bergin 
C (2017) Open Forum Infectious Diseases, 4(1): ofw242.  
http://www.drugsandalcohol.ie/28177/ 
Human immunodeficiency virus (HIV)-associated 
neurocognitive disorders occurs in 20%-50% of HIV-positive 
patients. We undertook this study to assess the prevalence 
of a positive screen for cognitive impairment in the clinic 
population at our institution and to demonstrate the 
feasibility of implementing a screening program in routine 
clinical encounters.
The study highlights the necessity for a structured, 
prospective, large-scale screening program for cognitive 
impairment across countries with limited resources and 
demonstrates the feasibility of easily implementing this with 
minimal training.
Treatment for opioid use and outcomes in older adults:  
a systematic literature review 
Carew AM and Comiskey C (2018) Drug and Alcohol 
Dependence, 182: 48—57.  
http://www.drugsandalcohol.ie/28129/ 
Historically, issues relating to problem substance use among 
older people have received little attention, and have only 
recently been recognised. 
Findings suggest that little is known about treatment 
outcomes among older people. Problematic drug use (of 
which opioids make up the largest proportion) had been 
incorrectly assumed to end as patients age. Defining an 
age limit for ‘older’ is important. Addiction and healthcare 
services must anticipate and prepare for increased demand 
by this group.
National Drugs Library
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Self-harm, methadone use and drug-related deaths 
amongst those registered as being of no fixed abode or 
homeless in Ireland 
Glynn RW, Lynn Ena, Griffin E, Fitzgerald M and Ward M 
(2017) Irish Medical Journal, 110(9): 631.  
http://www.drugsandalcohol.ie/27977/ 
This work aims to contribute to the evidence base regarding 
the health of those who experience homelessness in Ireland 
by collating data on methadone use, drug-related deaths 
and emergency department presentations due to self-harm. 
The number of drug-related deaths amongst those of NFA or 
homeless and who died in Dublin fluctuated from 2004-13 
with an overall upward trend. There is an urgent need to 
adequately resource and coordinate those services which 
aim to address factors (social and health inequalities, mental 
ill-health and addiction) which lead people into — and 
prevent them exiting from — homelessness.
Concurrent use of alcohol interactive medications and 
alcohol in older adults: a systematic review of prevalence 
and associated adverse outcomes 
HHolton AE, Gallagher P, Fahey T and Cousins G (2017)  
BMC Geriatrics, 17(1): 148.  
http://www.drugsandalcohol.ie/27636/ 
The aim of this study was to systematically review the 
prevalence of concurrent use of alcohol and alcohol-
interactive (AI) medicines in older adults and associated 
adverse outcomes.
While there appears to be a high propensity for alcohol-
medication interactions in older adults, there is a lack of 
consensus regarding what constitutes an AI medication. 
An explicit list of AI medications needs to be derived 
and validated prospectively to quantify the magnitude 
of risk posed by the concurrent use of alcohol for 
adverse outcomes in older adults. This will allow for risk 
stratification of older adults at the point of prescribing, and 
prioritise alcohol screening and brief alcohol interventions 
in high-risk groups.
A multi-country study of harms to children because of 
others’ drinking 
Laslett AM, Rankin G, Waleewong O, Callinan S,  
Hoang HTM, Florenzano R, et al. (2017) Journal of Studies  
on Alcohol and Drugs, 78(2): 195—202.  
http://www.drugsandalcohol.ie/27620/ 
This study aims to ascertain and compare the prevalence  
and correlates of alcohol-related harms to children  
cross-nationally.
Family-level drinking patterns were consistently identified as 
correlates of harm to children because of others’ drinking, 
whereas sociodemographic factors showed few obvious 
correlations.
Home manufacture of drugs: an online investigation  
and a toxicological reality check of online discussions  
on drug chemistry 
Hearne E, Alves EA, Van Hout MC and Grund JPC (2017) 
Journal of Psychoactive Drugs, 49(4): 279—88. 
http://www.drugsandalcohol.ie/27580/ 
We illustrate here how online communal folk pharmacology 
of homemade drugs on drug website forums may actually 
inform home manufacture practices or contribute to the 
reduction of harms associated with this practice. 
Drug discussion forums should consider re-evaluating their 
policies on chemistry discussions in aiming to reach people 
who cannot or will not refrain from cooking their own drugs 
with credible information that may contribute to reductions 
in the harms associated with this practice.
Characteristics of methadone-related overdose deaths  
and comparisons between those dying on and off opioid 
agonist treatment (OAT): a national cohort study 
Van Hout MC, Crowley D, Collins C, Barry A, Lyons S and 
Delargy I (2017) Heroin Addiction and Related Clinical 
Problems. Early online. 
http://www.drugsandalcohol.ie/27568/ 
We describe characteristics of methadone related overdose 
deaths and assess if differences exist between those dying 
on and off opioid agonist treatment (OAT).
Methadone related fatal overdose is a significant cause  
of death in young Irish, who share many characteristics  
with other drug related deaths. Improved monitoring,  
risk assessment and OAT retention strategies is warranted 
to inform national drug overdose plans and overdose 
prevention.
A cross-national study on gender differences in  
suicide intent 
Freeman A, Mergl R, Kohls E, Székely A, Gusmao R, Arensman 
E, et al. (2017) BMC Psychiatry, 17(1): 234. 
http://www.drugsandalcohol.ie/27550/ 
The aim of this study is to explore gender differences in 
suicide intent in a cross-national study of suicide attempts. 
The secondary aims are to investigate the gender differences 
in suicide attempt across age and country.
Considering the differences in suicidal intent between 
males and females highlighted by the current study, gender 
targeted prevention and intervention strategies would be 
recommended.
Recent publications continued
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Anxiety and depression among patients with alcohol 
dependence: co-morbid or substance-related problems? 
Gallagher C, Radmall Z, O’Gara C and Burke T (2017)  
Irish Journal of Psychological Medicine. Early online. 
http://www.drugsandalcohol.ie/27544
The aim of this study was to characterise rates of co-
morbid psychiatric symptoms among a group of individuals 
commencing treatment for alcohol dependence, and to 
examine the stability of these symptoms following treatment 
of the alcohol problem.
The significant change in rates of reported symptoms 
following completion of treatment suggests that a large 
proportion of symptoms reported at treatment entry were 
substance related. Diagnosing co-morbid conditions is 
best left until after a period of abstinence during which 
the alcohol problem has been treated. Assessing for co-
morbidity at time of treatment seeking is likely to result 
in inappropriate co-morbid diagnoses being made and 
inappropriate or unnecessary treatments being prescribed 
for such individuals.
Drinking context and cause of injury: emergency 
department studies from 22 countries 
Korcha RA, Cherpitel CJ, Bond J, Ye Y, Monteiro MG and 
Chou P (2017) Journal of Substance Use. Early online.  
http://www.drugsandalcohol.ie/28096/ 
It is estimated that up to a third of injuries requiring 
emergency department (ED) admission are alcohol-related. 
While injuries that are alcohol-related are unsurprising to  
ED staff, less is understood about the precursors to the 
injury event.
Understanding the cause and context of injury and alcohol 
use are important components to evaluation  
and development of alcohol policies.
RESPONSES
Working with clients with addiction:  
what psychologists need to know
O’Driscoll C and Foy S (2017) The Irish Psychologist,  
43(12): 16—20.  
http://www.drugsandalcohol.ie/27973/ 
Addiction is a common problem that practitioner 
psychologists face with their clients. It is however, the view 
and experience of the authors that specialised training in 
addiction treatment for psychologists is sparse, inconsistent 
and incomprehensive. 
This article aims to give some context to the nature of 
these issues and the challenges facing practitioners, offer 
an overview of evidence in the treatment of addiction, and 
finally conclude with some guidance to psychologists in the 
treatment of these issues in the psychotherapeutic context.
How do individuals develop alcohol use disorder after 
bariatric surgery? A grounded theory exploration 
Yoder R, MacNeela P, Conway R and Heary C (2017)  
Obesity Surgery. Early online.  
http://www.drugsandalcohol.ie/28007/ 
The aim is to construct a theory to explain the development 
of AUD (alcohol use disorder) among a sample of individuals 
who reported problematic drinking following RYGB (Roux-
en-Y gastric bypass).
The theoretical framework of ‘filling the void’ adds to 
contemporary research that conceptualises AUD  
behavioural substitution as ‘addiction transfer’ by  
describing the process by which the phenomenon occurs  
as well as the characteristics of participants. The clinical 
implication of this research is to advocate for a reshaping 
of treatment of RYGB patients, with increased psychological 
input following surgery.
Experiences of men with psychosis participating in a 
community-based football programme 
Moloney L and Rohde D (2017) Irish Journal of  
Occupational Therapy, 45(2): 100—111.  
http://www.drugsandalcohol.ie/27981/ 
This study highlights the value and meaning of participation 
in football for men with psychosis, as well as demonstrating 
the longer-term feasibility of football as a therapeutic 
medium in Occupational Therapy mental health service 
provision. Findings could help to promote the routine use of 
sports interventions to mental health services.
Risk of repeated self-harm and associated factors in 
children, adolescents and young adults 
Bennardi M, McMahon E, Corcoran P, Griffin E and  
Arensman E (2016) BMC Psychiatry, 16(1): 421.  
http://www.drugsandalcohol.ie/27940/ 
Repeated self-harm represents the single strongest risk 
factor for suicide. To date no study with full national 
coverage has examined the pattern of hospital repeated 
presentations due to self-harm among young people.
Young people with the highest risk for repeated self-harm 
were 15—19-year-old females and 20—24-year-old males. 
Self-cutting was the method associated with the highest 
risk of self-harm repetition. Time between first self-harm 
presentations represents an indicator of subsequent 
repetition. To prevent risk of repeated self-harm in young 
people, all individuals presenting at emergency departments 
due to self-harm should be provided with a risk assessment 
including psychosocial characteristics, history of self-harm 
and time between first presentations.
Recent publications continued
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Implementing a tobacco-free hospital campus in Ireland: 
lessons learned 
McArdle D and Kabir Z (2017) Irish Journal of  
Medical Science. Early online. 
http://www.drugsandalcohol.ie/27706/ 
The aims of this study are to examine hospital staff 
awareness and to assess the progress of selected HSE health 
care facilities towards a TFC (tobacco-free campus) policy.
Staff awareness of the HSE TFC policy across selected health 
care facilities in Ireland is positive but is not sufficient. 
There are gaps in the implementation process of the HSE 
TFC policy in the health care facilities. Therefore, proper 
communication on the importance of the ENSH-Global 
standards and cessation training to all staff is necessary to 
help reduce smoking rates across the health care facilities 
and also to move towards a Tobacco Free Campus in Ireland.
Exploring patient characteristics and barriers to hepatitis 
C treatment in patients on opioid substitution treatment 
attending a community based fibro-scanning clinic 
Crowley D, Cullen W, Laird E, Lambert JS, McHugh T, Murphy 
C and Van Hout MC (2017) Journal of Translational Internal 
Medicine, 5(2): 112—119.  
http://www.drugsandalcohol.ie/27666/ 
Hepatitis C virus (HCV) infection is a major public health 
issue. There is substandard uptake in HCV assessment 
and treatment among people who inject drugs (PWID). 
Community fibroscanning is used to assess disease severity 
and target treatment.
The study highlights the usefulness of community 
fibroscanning. Identifying barriers to treatment in this cohort 
affords an opportunity to increase the treatment uptake. The 
availability of afternoon clinics and enhanced prison linkage 
are warranted.
Core addiction medicine competencies for doctors,  
an international consultation on training
Ayu AP, El-Guebaly N, Schellekens A, De Jong C, Welle-Strand G 
and Small W (2017) Substance Abuse, 38(4): 483—87. 
http://www.drugsandalcohol.ie/27667/ 
We undertook this study to assess the views of international 
scholars, representing different countries, on the core set  
of addiction medicine competencies that need to be 
covered in medical education.
While it is unclear whether a global curriculum is needed, 
a consensus on a core set of principles for progression 
of knowledge, attitude and skills in addiction medicine to 
be developed at each educational level amongst medical 
graduates would likely have substantial value. 
Community pharmacist experiences of providing needle  
and syringe programmes in Ireland 
McVeigh J, Hearne E, Bates G and Van Hout MC (2017) 
Research in Social Administration and Pharmacy,  
13(4): 767—77. 
http://www.drugsandalcohol.ie/27519/ 
The aim was to understand and illustrate pharmacist 
experiences of providing NSP (needle and syringe 
programmes).
Further enhancement of NSP coverage and targeted service 
delivery within national care pathways for drug and alcohol 
services is warranted.
 
Recent publications continued
